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Bone metastasis commonly causes morbidity and mortality in patients with advanced 
breast cancer. Despite, better prognoses for breast cancer patients in general, the outlook for 
those with bone metastasis remains grim, with less than one quarter of those afflicted surviving 
past five years. Fundamental insights into how microenvironmental cues drive bone metastasis 
may help to fight the disease. Hydroxyapatite (HA) is a calcium-phosphate mineral that is found 
both in the bone, to which breast cancer spreads during metastasis, and in the breast tissue of 
many cancer patients in the form of microcalcifications. Despite the consistent presence of this 
bioactive mineral in the breast tumor microenvironment, little evidence currently exists to 
implicate it in cancer pathogenesis. Using a tissue engineering-inspired scaffold that incorporates 
HA in conjunction with hydrothermal techniques to synthesize well-defined mineral, tumor cell-
HA interactions were investigated. Soluble factors from these scaffold cultures were collected, 
analyzed, and used on other cells to study cell-cell interactions pertinent to bone metastasis. 
Xenograft models were used to understand how exposure to mineral might affect metastasis in 
vivo, and human patient samples were analyzed to validate findings with our scaffold models. 
The results suggest that the presence of hydroxyapatite promotes tumor cell growth and 
adhesion, as well as production of factors such as interleukin-8 (IL-8) that drive bone 
degradation, a cause of bone pain and pathological fracture in metastasis. Furthermore, tumor 
cell interactions with hydroxyapatite change gene expression patterns and promote the activation 
of a migratory axis by enriching levels of stromal-derived factor-1 (SDF-1), possibly dictating 
the propensity of breast cancer to metastasize to bone. Exposure to mineral promoted bone 
colonization by tumor cells in mice, and preliminary results indicate that IL-8and the receptor for 
SDF-1 are elevated in human patients with microcalcifications. The data also suggest that 
 material properties of HA affect cell behavior, as larger, more crystalline particles stimulate the 
most IL-8 production, while smaller, less crystalline particles promote adhesion and growth. 
Integrin interactions are potentially involved in controlling cell-HA interactions, as it was found 
that blocking  integrin binding to HA-adsorbed proteins such as osteopontin and fibronectin 
attenuated many of the observed behaviors stimulated by HA. Hydrothermal synthesis of HA and 
mineral-containing scaffolds emerged as excellent tools to study breast cancer biology, revealing 
that microenvironmental HA may play an important role in driving bone metastasis. 
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CHAPTER 1: INTRODUCTION 
1.1 Breast Cancer Metastasis to Bone 
Of the nearly 40,000 estimated annual deaths that result from breast cancer, roughly 70% 
will be associated with patients afflicted with bone metastasis (1-3). Including facing severely 
decreased survival odds, patients with bone metastasis will suffer from further complications 
such as pathological incidence of fracture, nerve compression, severe bone pain, hypercalcaemia, 
and an overall decrease in quality of life (4). Metastasis involves cells from the initial tumor 
breaking free and disseminating to distant organs and tissues via lymphatic and blood vessels, 
and subsequently colonizing and forming secondary tumors (Fig. 1.1). It is considered a hallmark 
of malignancy, and in the case of breast cancer, it is known to occur with high frequency in the 
skeletal system (5). While previous research has revealed specific alterations in genetic 
expression patterns that are correlated with the predilection for breast cancer to metastasize to 
bone, the potentially instructive influence of the tumor microenvironment in this respect remains 
unclear. 
Breast cancer generally affects the lining of ducts or lobules in the mammary tree. The 
disease itself is heterogeneous, and it is diagnosed based on a formalized semiquantitative 
staging system used by oncologists and approved by the American Joint Committee on Cancer. 
Masses in breast tissue range from totally benign (stage 0) to highly metastatic (stage IV) (6). 
Along this continuous spectrum, tumors may be roughly divided into two forms: invasive 
carcinomas that are infiltrating and malignant and ductal carcinomas in situ (DCIS) that may 
later become invasive. Invasive tumors that spread to lymph nodes and are highly vascularized 
are prone to metastasis. Around 30% of breast tumor diagnoses are invasive and associated with 
2 
metastatic disease (7). Researchers suspect that in the vast majority of these cases, skeletal 
metastases are present (1, 3, 8).  
 
 
Figure 1.1: Tumor Metastasis 
Tumor metastasis is a stepwise process. (1) Angiogenesis: Tumor cells first recruit blood vessel and 
generate tumor vasculature. (2) Intravasation: Following vascularization, cancer cells must adhere to and 
invade through the basement membrane of vessels. (3) Embolism: After penetrating vasculature, cells are 
dislodged from lumen walls and circulate through the blood. (4) Colonization: Once cells reach the site of 
metastasis, they are arrested in the capillary bed of the tissue. (5) Secondary Growth: In response to 
microenvironmental cues (soluble factors, cell-cell interactions, etc.), colonized cells proliferate and 
establish a secondary tumor.  
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While breast cancer remains the second leading cause of cancer related death among American 
women, significant improvements have been made through better diagnosis and treatment 
options in the past decade (9). In fact, 34% of the overall decline in female cancer deaths over 
the last 10 years are due to better available care options for breast cancer victims (2). Many of 
these have emerged due to advances in basic research. For instance, investigations into gene 
expression have shown the importance of estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 (HER2) for many cancers (10, 11). These 
discoveries have led to the development and therapeutic use of receptor inhibitors such as 
trastuzumab (for HER2) and tamoxifen (for ER), which have been very effective in combating 
certain subtypes of breast cancer (12, 13). Diagnosis and increased breast cancer awareness are 
also viewed as having a positive effect, as monthly self breast exams and regular clinical breast 
exams aid in early detection, which greatly increases survival rates (7, 9). 
Despite the positive developments in breast cancer survival, significant challenges 
remain. In particular, most of the developments in molecular-based therapies are targeted against 
breast cancer subtypes with high expression of ER, PR, or HER2. Unfortunately, so-called 
“triple negative” breast cancers that grow aggressively in the absence of these receptors remain 
impervious to these treatment options, and are known to generate metastases (14). Similarly, 
while early detection is effective in increasing survival rates, many tumors are not or cannot be 
detected in early stages, and the five-year survival rate for these patients, many of whom are 
afflicted with bone metastases, is just 23% (9). There is also evidence that bone metastases are 
resistant to conventional chemotherapeutics, further highlighting the need for fundamental 
insight into this devastating disease (15). 
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Stephen Paget is credited with formalizing the “seed and soil” concept for metastasis in 
the late 19
th
 century (16), and many researchers have pursued this line of thinking in 
investigating why metastatic breast cancer has such a strong avidity for bone (8, 17, 18). Recent 
studies have demonstrated that within breast tumors, heterogeneous expression of specific genes 
predisposes a certain subset of cells to metastasize to bone (18). Still, no concrete evidence on 
how this “bone metastasis signature” emerges or is regulated exists. In recent times, the critical 
nature of the tumor microenvironment in dictating cancer cell behavior has come to light, and it 
seems likely that microenvironmental control through cues such as cell-cell interactions, cell-
ECM interactions, and biomechanical stimuli plays a role in metastasis as well (19-21) (Fig. 1.2). 
The bone matrix is uniquely defined the presence of the inorganic mineral hydroxyapatite (HA), 
a material known to bioactively affect cell behavior (22, 23). Thus, for the specific context of 
bone metastasis, the interaction between breast cancer cells and mineral should be investigated. 
This interaction occurs both within the bone, due to the presence of the skeletal mineral 
hydroxyapatite (HA), and at the primary site in the breast where microcalcifications are known 
to form (24, 25). Thus far, correlation has been shown between breast cancer cell mitogenesis 
and the presence of HA (24). Additionally, studies of both animal and human samples have 
shown a correlation between the presence of HA and general malignancy (26, 27). These 
findings suggest that HA may play a significant role in tumor development and driving bone 
metastasis.  
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Figure 1.2: Tumor Microenvironment 
The tumor microenvironment comprises the local area around a tumor and the various cellular inputs 
contained in this space. The inputs are a diverse set of physicochemical cues that enable tumors to survive 
and advance. Study of the microenvironment will help in understanding how external influences on tumor 
cells permit and promote metastatic disease.  
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1.2 Mineralization in the body 
Tissue mineralization is a fundamental and critical process for vertebrates, helping to 
imbue bone and teeth with their structural integrity (25). For humans, the normal mineral that is 
found in the skeleton is chemically similar to geological HA (Ca10(PO4)6)(OH)2), though it is 
generally highly substituted, less crystalline, and more soluble (28). The material and 
microstructural properties of bone HA are also dynamic, being observed to change as a function 
of aging and various skeletal pathologies (26, 29). In bone, HA is organized along collagen 
fibrils, and it makes up the majority of the dry weight of the tissue (30). It is known to associate 
and interact strongly with a variety of noncollagenous proteins, such as osteopontin and 
fibronectin, that are capable of supporting cell adhesion, and could be implicated in promoting 
the colonization of metastatic breast cancer cells (31, 32).  
While mineral is predominantly found in normal tissue such as bone and teeth, calcium-
based mineral is also observed ectopically through soft tissues in a variety of pathologies. 
Kidney stones, atherosclerosis, and various skin disorders are all associated with pathological 
calcification (33, 34). Small degrees of ectopic calcification are not unusual, but radiological 
studies have shown that the presence of microcalcifications in breast tissue can be a precursor to 
malignant disease (24, 27). Currently, mammograms, which can reveal flecks of mineral in the 
breast, are one of the most important diagnostic tools for mammary tumors (9). There is evidence 
to suggest that tumor cell interactions with microcalcifications are connected to subsequent bone 
metastasis. Firstly, breast tumor cells in tumors with microcalcifications have been found to 
produce elevated levels of bone matrix proteins such as bone sialoprotein (BSP) and osteopontin 
(OPN) (18, 35, 36). Secondly, there is evidence to suggest that breast tumors that tend to display 
microcalcifications are also more likely to metastasize to bone relative to visceral targets (15, 35, 
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37). Unfortunately, despite these observations, there is still no predictive power that can be 
ascribed to mammogram-based diagnoses because an overwhelming majority of patients that 
have microcalcifications remain disease free (>99%) according to the American Cancer Society. 
Additionally, there is a lack of mechanistic understanding on how breast cancer cells are affected 
by mineral due a dearth of appropriate culture systems with which to probe this type of 
interaction. For these reasons, the presence of microcalcifications has largely been regarded until 
now as simply a primary diagnostic marker, albeit a crucial one. However, recent work with 
improved spectral analysis has revealed that breast microcalcifications can be divided into two 
distinct subgroups: type I, which are composed of calcium oxalate dihydrate, the mineral found 
in kidney stones; and type II, which are composed of HA as in bone. Interestingly, type I 
microcalcifications have been found to be associated strictly with benign, non-invasive growths, 
while type II microcalcifications seem to strongly promote malignancy and metastasis (27). It is 
certainly notable that breast cancer that is exposed to HA mineral at the primary site is more 
likely to metastasize to HA-rich bone, and these recent findings demonstrate the need to study 
the interaction between biological mineral and breast cancer cells carefully.  
1.3 Tumor Microenvironment 
Advances in genetics have yielded an enormous amount of insight into tumor biology. 
Common mutations underlying malignant transformation and genes that serve as risk factors for 
cancer susceptibility have been identified (38). Nonetheless, it is increasingly evident that a 
comprehensive understanding of cancer and metastasis will require an understanding of how 
external factors drive tumor cell behavior. In this regard, investigation of pertinent 
microenvironmental cues is being undertaken. Already, microenvironmental control of cancer 
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has been implicated in tumor progression and multidrug resistance, and a number of compounds 
targeted at the tumor microenvironment are in clinical trials (19, 39). 
1.3.1 Soluble Factors and Paracrine Signaling 
Whenever and wherever tumors develop, they secrete a slew of soluble factors including 
growth factors, hormones, and cytokines. Numerous findings show that they also deregulate the 
secretory activity of neighboring cells, causing further perturbation of normal physiology (40). 
Paracrine signaling is the most common method of cell-cell communication, and it occurs when 
secreted molecules from tumor cells activate intracellular signaling cascades in other cells via 
specific receptors, and vice versa. Inception of tumor angiogenesis and cancer-activated 
inflammation, both hallmarks of cancer, are mediated by soluble factors in the tumor paracrine 
signaling network (5, 41, 42). The complete list of soluble factors that are involved in tumor 
paracrine signaling is innumerable, but molecules such as vascular endothelial growth factor 
(VEGF) and interleukin-8 (IL-8) are known to be important players in breast cancer progression 
(43, 44). Perhaps one of the most widely-publicized anticancer therapies of all time, Avastin 
(bevacizumab), is a monoclonal antibody against VEGF that was targeted against the soluble 
factor to inhibit tumor angiogenesis (45). Despite its associated controversy and limited clinical 
success, the hype surrounding Avastin reflects the realization of the paramount importance of 
paracrine signaling in the tumor microenvironment. 
1.3.2 Tumor-Extracellular Matrix (ECM) Interactions 
Tumor invasion and cancer cell colonization are both fundamentally dependent on 
interaction with the ECM to provide anchorage and insoluble signaling cues. Even in mineralized 
tissue, cancer cells only interface directly with adhesive proteins that are intimately associated 
with HA. Common ECM proteins such as collagen, fibronectin, and laminin provide structural 
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binding and can initiate intracellular signaling cascades via integrin receptors on cancer cells (44, 
46). Additionally, in the case of metastatic breast cancer, there is a high prevalence of other 
adhesive proteins such as BSP and OPN, which can also induce signals that may promote bone 
metastasis via integrins and other surface receptors (36). BSP and OPN both contain long 
negatively-charged amino acid sequences that facilitate their binding to HA, and they possess 
RGD sequences that enable cell attachment (47, 48). Tumor-ECM interactions are extremely 
dynamic: not only do tumor cells vary their integrin surface presentation in a spatiotemporally-
dependent manner, they also pathologically remodel ECM relative to normal tissue (21).  
1.4 Cellular compartment of the bone microenvironment 
For breast cancer metastases, interacting with native bone cells represents a critical step 
in priming the bone microenvironment to establish a pre-metastatic niche that can be colonized. 
The bone microenvironment is primarily composed of two major specialized cell types: the 
bone-forming osteoblasts, and the bone-resorbing osteoclasts. Within the trabecular bone, the 
initial site of metastatic colonization, marrow is also rich in mesenchymal stem cells (MSCs), 
which are multipotent and capable of differentiating into various connective tissue lineages (49) 
and hematopoietic stem cells (HSCs), which give rise to all blood cells and osteoclasts 
themselves (49, 50).(Fig. 1.3). Many investigations have focused on the relationship between 
cancer cells and osteoclasts, as metastatic lesions from mammary tumors tend to be characterized 
by bone loss and an overall osteolytic phenotype. Indeed, several studies have convincingly 
shown that breast cancer cells promote excessive osteoclast activity (4, 51). It has been suggested 
that osteolysis is a means through which breast cancer can access the growth factor depots within 
bone, and that this enhanced osteoclast activation is part of a vicious positive feedback cycle by 
which breast cancer maintains itself in bone (1, 52). 
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Figure 1.3: Bone Microenvironment 
Skeletal metastasis exposes mammary tumor cells to the unique combination of cues found in the bone 
microenvironment. Cell-cell interactions via endocrine or paracrine signaling take place between tumor 
cells and native bone cells: osteoclasts, which resorb bone, and osteoblasts, which help in laying down 
new bone. Undifferentiated mesenchymal stem cells are also present and can interact metastasizing cells. 
Finally, mammary tumor cells are exposed to hydroxyapatite, the bone mineral.  
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Pit New Mineral
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The role of MSCs in breast cancer metastasis has been more difficult to resolve, due to 
their highly multifunctional nature. For example, past studies have shown that MSCs contribute 
to tumor angiogenesis by upregulating their expression of vascular endothelial growth factor 
(VEGF) (41).  Other work has suggested that MSCs may secrete many pro-inflammatory 
cytokines that aid in tumor development and survival (53). In the specific context of metastasis, 
some studies indicate that MSCs mobilize tumor cells in a paracrine fashion by directly 
enhancing motility, while others suggest MSCs as the main stromal cell supporting metastatic 
recruitment (54, 55). Furthermore, observations that metastatic priming may require endocrine 
signaling suggest that tumor cells and MSCs may interact even at distant sites (56) to establish a 
pre-metastatic niche. It is known that the bone marrow is rich in stromal-derived factor 1 (SDF-
1), a molecule that is also suspected to drive bone metastases.  MSCs are a cell type that produce 
high levels of SDF-1 (57), suggesting a potential role for MSCs in tumor cell recruitment. 
However, there is still a lack of work on how SDF-1 levels are regulated during incipient stages 
of metastatic bone disease. It would seem that work is needed to determine whether or not MSC 
expression of SDF-1 is altered to promote pre-metastatic niche formation and mammary tumor 
cell recruitment. Still, the overall breadth of results suggesting a connection between MSCs and 
breast cancer progression illustrate how understanding this cell-cell interaction will provide 
fundamental insight into bone metastasis.  
1.5 Synthetic HA and mineral-containing model systems 
The lack of existing mineral-containing tissue culture systems severely limits the ability 
to study cancer cell-mineral interactions in vitro. Additionally, clinical studies, illustrate the need 
to carefully control HA properties such as crystallinity, particle size, and substitution for in vitro 
experiments (27). Significant work in the field of biomineralization has revealed much insight 
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into how to make mineralized films and gels, but few of these systems are suitable for cell 
culture, due to limitations in oxygen transport and temperature control (25, 32). A multitude of 
techniques for the creation of synthetic HA have been employed, but as particles alone, they also 
cannot easily be presented to cells (58). Moreover, few studies have truly utilized technique for 
the synthesis of physiologically relevant crystal characteristics. There is evidence to suggest that 
crystal properties affect cellular behavior (59),  but few systematic studies that model changing 
mineral properties that are associated with effects observed in pathologies have been performed. 
Scaffold systems designed by tissue engineering principles can serve as a vehicle to present 
mineral particles to cells. Originally designed for bone tissue engineering, scaffold systems are 
biocompatible and support cell adhesion (60). Based on the current state of the field, it is 
apparent that to recapitulate tumor cell-mineral interactions, application of controlled mineral 
synthesis, biomaterials science, and tissue engineering design will be required for the creation of 
a functional model. 
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1.6 Research Objectives 
Hydroxyapatite mineral is a strikingly unique component of both the metastatic and 
primary tumor environment for breast cancer. With increasing evidence suggesting that mineral 
plays an active role in affecting tumor cell behavior, exploring how it may drive breast cancer 
metastasis to bone is a natural pursuit. More broadly, investigating the complex interplay of 
tumor cells with mineral, bone and stromal cells, and matrix proteins and determining how these 
microenvironmental cues affect the paracrine signaling network and drive disease progression 
may provide insights that aid in revealing novel points for therapeutic intervention. 
I hypothesize that the interaction between mineral and breast cancer cells promotes 
malignancy and underlies the observed affinity of resulting metastases for bone and the 
subsequent osteolytic phenotype. I have investigated this hypothesis by systematically exploring 
the following three sub-hypotheses: 
1. Mineral promotes osteoclastogenesis by enhancing tumor cell secretion of 
osteolytic factors 
2. Exposure to microcalcifications/mineral primes mammary tumor cells for 
colonization of bone by stimulating MSC-driven recruitment 
3. Crystal properties affect tumor cell-mineral interactions and regulation of 
malignant phenotype 
In the search for innovative ways to fight breast cancer, it is logical to target bone 
metastases, which remain difficult to deal with currently. Understanding the influence of the 
microenvironment in driving this process will contribute to the elucidation of the molecular 
mechanisms of bone metastasis, helping to reveal the potential susceptibilities of metastases for 
treatment option. Since mineral is a salient feature in the stepwise metastasis cascade, and 
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because it is already used as a diagnostic marker, it is sensible to study its role as a 
microenvironmental controller.  
1) Mineral promotes osteoclastogenesis by enhancing tumor cell secretion of osteolytic factors 
A mineral-containing three-dimensional (3-D) scaffold system was engineered to present 
HA to a metastatic human breast cancer cell line (MDA-MB231) to monitor changes in secretory 
behavior in response to the mineral. The system was evaluated to confirm that mineral is reliably 
exposed to cells, and baseline parameters such as adhesion and tumor cell growth were 
measured. Changes in the secretion levels of IL-8 were also specifically assessed, as previous 
studies suggested that this molecule could independently induce osteoclast differentiation and 
activity (51). Furthermore, clinical studies have indicated that IL-8 expression is associated with 
increased malignancy (61). Conditioned media was collected from mineral-containing culture 
models, and this media was used to culture murine osteoclast precursor cells (RAW 264.7) to 
evaluate the effects of tumor-derived soluble factors on differentiation and resorptive activity. 
Inhibitory antibodies were used to definitively show the mechanistic role of IL-8 in driving 
osteolysis.    
2) Crystal properties modulate cell-ECM interaction to alter tumor cell behavior and regulate 
the malignant phenotype 
A hydrothermal aging approach was used to create synthetic HA with varying particle 
size and crystallinity. This novel process involved two steps: first precipitating calcium 
phosphate through standard solution-based techniques, and subsequently drying and aging them 
with well-defined heating schedules in a non-stirred pressure vessel. In this manner, 
homogeneous populations of HA crystals were synthesized before being incorporated into a 3-D 
scaffold for probing interactions with cancer cells. Basic bioactivity parameters were tested in 
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the scaffolds as a function of crystal properties, including protein adsorption, cellular growth, 
and cellular adhesion. The specific capacity of various crystals to adsorb adhesive peptides was 
measured and correlated with adhesion of MDA-MB231 cells. IL-8 expression was also tested to 
see how it varied with crystal characteristics.  
3) Exposure to microcalcifications/mineral primes mammary tumor cells for colonization of 
bone by stimulating MSC-driven recruitment 
To understand how cell-mineral interactions might mediate actual recruitment of breast 
cancer cells to the bone, the comprehensive effects of the mineral-containing scaffolds were 
determined. Expression of bone metastasis genes in mineral-containing scaffolds were 
investigated to see whether these genes may be activated by microenvironmental-HA. Trends 
observed with MDA-MB231 cells were reassessed with MCF10A.DCIS cells (62). The effect of 
tumor-derived IL-8 on MSCs was explored, and transwell systems were used to observe 
migration patterns of cancer cells that were preconditioned in mineral-containing scaffolds and 
then exposed to MSC secretions. Generally, the potential role of MSCs in recruiting mineral-
exposed breast cancer cells was studied. This was done to recapitulate the effect of 
microcalcifications that may drive bone metastasis physiologically.  
MDA-MB231 subpopulations with differential tissue tropism were previously developed 
via in vivo serial passaging and generously provided by Dr. Joan Massague (18). Though it has 
been thought that these subpopulations inherently possess different  gene expression profile 
relative to one another, the ability of HA to “re-program” these cells was assessed by expression 
analysis. Subsequently, pre-exposure to mineral in scaffolds was tested for the capacity to affect 
tissue tropism through a colonization mouse model via intracardiac injection. Finally, a clinical 
exploration was completed in collaboration with Memorial Sloan Kettering Cancer Center 
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(MSKCC). Pathological reports, histological analysis, mammography, and immunostaining for 
IL-8, were blindly performed in conjunction with a team of clinicians, and the correlation 
between patient outcome, appearance of microcalcifications, and IL-8 levels was determined.  
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CHAPTER 2: A NOVEL 3-D MINERAL-CONTAINING TUMOR MODEL TO STUDY 
BREAST CANCER BONE METASTASIS 
PUBLISHED IN PLOS ONE (63) 
2.1 Contributors 
Christine Kowalczweski contributed to this chapter by maintaining cultures of RAW 
264.7 cells and performing differentiation studies. Christine also performed image analysis to 
quantify TRAP staining of differentiation RAW 265. 7 cells. Ramya Tadipatri conducted 
experiments with Ibandronate, including viability assessment. Both Ramya and Christine 
fabricated scaffolds that were used in this study. I performed all other experiments and designed 
the study with Dr. Claudia Fischbach.  
2.2 Introduction 
Bone metastasis, the spread of tumor cells to the skeleton, is a frequent cause of 
morbidity and mortality in patients with advanced cancers. Seventy-percent of breast cancer 
patients with advanced disease develop bone metastases (3), which lead to severe bone pain, 
pathological fractures, hypercalcemia, and nerve compression (1, 4, 64). These debilitating 
skeletal events are a consequence of secondary tumor formation and pathological bone 
remodeling of predominantly osteolytic character (1). 
While organ-specific patterns of metastatic colonization are often mediated by site-
specific metastasis signatures (65), microenvironmental conditions in the bone are implicated in 
the pathogenesis of metastatic breast cancer. More specifically, mammary tumor cells located 
within bone up-regulate expression of growth factors and cytokines that stimulate 
osteoclastogenesis and inhibit osteoblast differentiation relative to the same cells located in soft 
18 
tissue sites (52, 66, 67). This process not only promotes pathological bone resorption, but also 
leads to the release of morphogens that further stimulate metastatic tumor growth and exacerbate 
the imbalance between bone formation and resorption. 
A variety of growth factors and cytokines drive the vicious cycle of bone metastasis by 
dually playing roles in tumor progression and bone remodeling. For example, vascular 
endothelial growth factor (VEGF) promotes bone metastasis by stimulating the formation of new 
blood vessels necessary for tumor growth and by regulating apoptosis and differentiation of 
tumor cells and osteoblasts (68, 69). Parathyroid hormone related protein (PTHrP), an osteoclast-
activating factor, is widely investigated for its role in metastasis mediated osteolysis, but 
interleukin-8 (IL-8) may be equally important because of its pro-angiogenic, pro-migratory, and 
osteoclastogenic activities (51, 66, 70-75). Whether or not specific bone microenvironmental 
conditions play a role in regulating the signaling by these pro-metastatic factors, however, 
remains unclear.  
The bone extracellular matrix (ECM) is a composite material that consists of an inorganic 
mineral phase dispersed throughout an organic matrix of collagen. The inorganic component of 
bone is primarily composed of the mineral hydroxyapatite (HA), a crystalline calcium phosphate 
phase with the molecular formula Ca5(PO4)3(OH) (76). While HA is noted for its role in 
imbuing bone with exceptional tissue stiffness and serving as a reservoir of ions (i.e., Ca2+ and 
PO43-), it also represents a bioactive material that modulates the behavior of both normal and 
transformed cells (24, 76, 77). For the specific case of bone metastasis, however, it remains an 
open question as to whether the presence of HA in the bone ECM affects the cellular and 
molecular interplay intrinsic to bone metastasis. 
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Three-dimensional (3-D) polymeric scaffolds represent highly innovative tools for 
recreating tumor microenvironmental conditions in culture (44, 78-80). In relation to 
conventional 2-D cultures, tumor cells maintained in 3-D scaffold-based, tissue-engineered 
tumor models exhibit characteristics that are more representative of their malignant behavior in 
vivo including increased angiogenic capacity, altered cell morphology, increased invasiveness, 
and enhanced resistance to cytotoxic drugs (44, 79). To specifically evaluate the role of HA in 
breast cancer bone metastasis we have developed a novel 3-D tumor model based on mineral-
containing scaffolds. This system allowed us to examine various stages of secondary tumor 
growth within bone microenvironments (i.e., initial colonization and subsequent tumor 
progression, osteolytic capability) under well-defined and pathologically relevant conditions in 
vitro. Our findings indicate for the first time that HA plays a critical role in controlling the 
osteolytic phenotype of breast cancer bone metastasis and that tissue-engineered, mineral-
containing tumor models may be an invaluable in vitro platform to reveal the underlying 
physicochemical and biological relationships. 
2.3 Results 
2.3.1 Physicochemical Characterization of Scaffolds 
Scaffold characterization was performed initially to determine the properties of the 
matrices and verify the presence of HA. EDS analysis indicated that HA was available for 
cellular interactions at the porous surface of the mineral-containing scaffolds, while non-mineral-
containing control scaffolds did not contain detectable amounts of calcium or phosphate (Fig. 
2.1A). Additionally, image reconstruction of microCT scans confirmed that HA was uniformly 
distributed throughout the mineral-containing scaffolds, whereas no X-ray absorption was 
detected for non-mineral-containing control scaffolds (Fig. 2.1B). Not surprisingly, DMA 
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analysis revealed that mineral-containing scaffolds exhibited compressive moduli that were 2-
fold higher than for non-mineral-containing control scaffolds (data not shown). These differences 
were related to the presence of HA as opposed to alterations in the microarchitecture, as mineral-
containing and non-mineral-containing control scaffolds exhibited similar wall thicknesses 
(mineral-containing scaffolds: 58 ± 27 μm, non-mineral-containing scaffolds: 50 ± 30 μm) and 
pore diameters (mineral-containing scaffolds: 432 ± 106 μm, non-mineral-containing scaffolds: 
451 ± 123 μm) (Fig. 2.1C, D).  
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Figure 2.1: Physicochemical characterization of scaffold system 
(A) HA in biomineral-containing scaffolds is available for cellular interactions as EDS analysis indicates 
Ca and P at the porous surface of the scaffolds, while no mineral was detected for blank control scaffolds. 
(B) MicroCT scans indicate that HA is uniformly distributed throughout biomineral-containing scaffold, 
but was not present blank control scaffolds. (C) Incorporation of HA did not alter the scaffold 
microarchitecture relative to blank control scaffolds. Scale bars represent 2 mm. (D) Image analysis of 
micrographs indicates that pore size and polymer wall thickness are similar for both biomineral-
containing and blank scaffolds. 
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2.3.2 Mineral-containing scaffolds promote MDA-MB231 adhesion and proliferation 
The ability of HA to affect breast cancer cell colonization and tumor growth within the 
bone microenvironment was next assessed by studying MDA-MB231 adhesion and proliferation 
within mineral-containing and non-mineral-containing control scaffolds. Relative to non-
mineral-containing scaffolds MDA-MB231 cells displayed greater penetration into the center of 
the mineral-containing scaffolds and increased adhesion onto HA-containing surfaces, as 
indicated by von Kossa staining of transverse histological sections of scaffolds (Fig. 2.2A). 
Quantification of seeding efficiency confirmed increased adhesion of tumor cells into mineral-
containing scaffolds (Fig. 2.2B). These differences were likely related to increased adsorption of 
adhesion proteins because Western Blot analysis showed that fibronectin was more readily 
adsorbed onto mineral-containing scaffolds as compared to non-mineral-containing scaffolds 
(Fig. 2.2C). Furthermore, blockade of fibronectin-binding integrins by pre-incubation with 
soluble RGD peptides decreased initial adhesion into mineral-containing scaffolds by 36%. 
Interestingly, the proliferative capacity of MDA-MB231 cells was also increased in the presence 
of HA, as a Hoechst DNA assay showed augmented cell numbers in mineral-containing scaffolds 
relative to control scaffolds (Fig. 2.3A). Similarly, MCF-7 cells exhibited a 20% increase in 
proliferation in mineral-containing scaffolds (data not shown) verifying the relevance of our 
findings with a second cell type. In agreement with these results, von Kossa and live/dead 
staining of the different MDA-MB231 tumor models indicated enhanced tumor tissue formation 
in the presence of HA after 5 days in culture (Fig. 2.3B, C). 
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Figure 2.2 Effect of HA on breast cancer cell adhesion 
(A) MDA-MB231 breast cancer cells adhere more efficiently to biomineral-containing scaffolds than 
blank scaffolds (**p<0.01). (B) Analysis of von Kossa stained histological cross-sections indicates that 
MDA-MB231 cells (stained red) penetrate to the center of biomineral-containing scaffolds (HA stained 
black) more effectively. Arrows and asterisks indicate representative scaffold walls and pores, 
respectively. Scale bars represent 2000 m. (C) Fibronectin adsorption within the polymer scaffold is 
increased in biomineral-containing scaffolds (lane 2) relative to blank scaffolds (lane 1) as indicated by 
Western Blot analysis of scaffold lysates. 
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2.3.3 Minerals promote tumor-mediated osteoclast differentiation and activity 
To assess a potential role of HA in the osteolytic phenotype of bone metastases, 
conditioned media were collected from the different tumor models, normalized to cell number, 
and used to test their effect on osteoclastogenesis of RAW 264.7 cells. Quantification of TRAP+ 
cells indicated that breast cancer cells cultured within 3-D non-mineral-containing scaffolds 
increased osteoclastogenesis as compared to control media that was not exposed to tumor cells 
and media collected from 2-D cultures (data not shown), but a much more dramatic effect was 
detected for mineral-containing tumor models (Fig. 2.4A, B). More specifically, media collected 
from mineral-containing tumor models increased osteoclast differentiation by 65% with respect 
to media collected from non-mineral-containing scaffold cultures and this effect was comparable 
to media supplemented with pro-osteoclastic RANKL (Fig. 2.4A, B). To ensure that tumor-
derived soluble factors in the mineral-containing culture media, and not soluble products of the 
scaffold itself (e.g., Ca
2+
, PO4
3-
), were directing osteoclast differentiation, we cultured RAW 
264.7 in cell-free scaffold-incubated media and found no differential effects on 
osteoclastogenesis relative to control media (data not shown). Accordingly, atomic absorption 
analysis did not yield detectable amounts of Ca
2+ 
and PO4
3-
 in media collected from non-mineral-
containing or mineral-containing scaffold cultures. Furthermore, the detected differences in 
osteoclastogenesis were not due to altered cell proliferation as an AlamarBlue assay showed 
similar cell numbers for all tested conditions (data not shown). Evaluation of osteoclast 
resorptive activity via analysis of Ca
2+
 release from Corning Bone Cell Assay Surfaces (81), 
confirmed our results by revealing significantly higher free Ca
2+
 concentrations in response to 
media collected from mineral-containing tumor models exceeding even the osteolytic potential 
mediated by 50 ng/mL RANKL (Fig. 2.4C).  
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Figure 2.3: Effect of HA on 3-D tumor tissue formation 
(A) Quantification of DNA indicates enhanced proliferation of MDA-MB231 cells within biomineral-
containing scaffolds as compared to blank scaffolds. (B) Analysis of von Kossa stained histological cross-
sections reveaed that 5 days after seeding, coherent tissue begins to form in biomineral-containing 
scaffolds but not blank scaffolds (MDA-MB-231 cells stained red, HA stained black). Scale bars 
represent 50 m. (C) Live and dead staining with calcein (green) and propidium iodide (red), 
respectively, shows increased cell number and tissue formation into pores of biomineral-containing 
scaffolds relative to control scaffolds, while the relative ratio of live to dead cells remains unchanged. 
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Figure 2.4: Osteoclastogenesis in response to conditioned media 
(A) Conditioned media collected from biomineral-containing tumor models (Biomineral-containing 
Conditioned Media) increased RAW 264.7 osteoclastogenesis relative to conditioned media collected 
from non-biomineral-containing tumor models (Blank Conditioned Media) as revealed by TRAP staining 
of large multinucleated cells. (B) Quantification of TRAP+ cells indicated that culture media collected 
from biomineral-containing scaffold cultures promoted RAW 264.7 osteoclastogenesis relative to control 
media (cDMEM) and media collected from blank scaffold cultures (82) in a manner that was similar to 
osteoclastic RANKL. Asterisks [*p<0.05, **p<0.01] and pound signs [#p<0.05, ##p<0.01] indicate 
statistical significance with respect to ‘cDMEM’ and ‘Blank’, respectively. (C) Conditioned media 
collected from biomineral-containing models enhances the resorptive activity of RAW 264.7 relative to 
all other tested conditions as indicated by 2-D culture on calcium phosphate disks and subsequent analysis 
of calcium release by a colorimetric assay. 
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2.3.4 Minerals enhance tumor-mediated osteoclastogenesis by up-regulation of IL-8  
The ability of HA to modulate the molecular interplay involved in tumor-mediated bone 
osteolysis was next tested by examining VEGF, PTHrP, and IL-8 as specific examples of 
tumorigenic and pro-osteoclastic factors. While VEGF secretion by MDA-MB231 cells was not 
affected by the scaffold type (Fig. 2.5A) and PTHrP was secreted at undetectable levels (<0.3 
pM) from either mineral-containing or non-mineral-containing tumor models (data not shown), 
IL-8 secretion was increased by 38% in mineral-containing scaffold cultures relative to tumor 
cells grown within non-mineral-containing scaffolds. Similarly, MCF-7 cells secreted 40% more 
IL-8 when cultured within mineral-containing scaffolds as compared to non-mineral-containing 
scaffolds. These differences were attributed to the inherent bioactivity of HA rather than the 
different mechanical stiffness of the matrices (non-mineral-containing scaffolds: 0.5 MPa, 
mineral-containing scaffolds: 1.1 MPa), as scaffolds with lower (50% HA) and higher HA 
content (200% HA) and thus lower (0.7 MPa) and higher elastic modulus (2.1 MPa) exhibited 
similar effects on breast cancer cell proliferation and IL-8 secretion (data not shown). IL-8 up-
regulation mediated pro-osteoclastic effects, as inhibition of this signaling by an IL-8 
neutralizing antibody yielded similar numbers of TRAP+, differentiated RAW 264.7 osteoclasts 
as media collected from non-mineral-containing scaffolds (Fig. 2.5B).  
Directed migration may be important to the fusion of RAW 264.7 cells to multinucleated, 
differentiated osteoclasts and we hypothesized that IL-8 may play a role in this process. Analysis 
of RAW 264.7 cell motility in response to the different culture media indicated that breast cancer 
cells maintained in mineral-containing tumor models induced RAW 264.7 migration more 
significantly relative to media collected from non-mineral-containing scaffold cultures or media 
supplemented with 50 ng/mL RANKL. Blockade of IL-8 signaling dramatically reduced motility 
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to levels comparable with cDMEM control media (Fig. 2.5C). Finally, both pit resorption and 
calcium release assays revealed that IL-8 inhibition more dramatically reduced the resorptive 
activity of RAW 264.7 cells cultured within media from mineral-containing tumor models 
relative to media collected from non-mineral-containing tumor models (Fig. 2.5D-F). 
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Figure 2.5: Osteoclastogenesis in response to HA-dependent IL-8 signaling 
(A) Tumor cells cultured within biomineral-containing scaffolds (black bars) up-regulated secretion of IL-
8 relative to culture within blank control scaffolds (white bars), while no effect was detected for VEGF 
secretion (*p<0.05). (B) Blockade of IL-8 signaling by addition of a neutralizing antibody inhibited the 
pro-osteoclastic effect of conditioned media collected from biomineral-containing tumors to levels 
comparable to non-biomineral-containing cultures (*p<0.05). (C) Transwell assays with conditioned 
media indicate that tumor cells cultured within biomineral-containing cultures markedly increase the 
motility of RAW 264.7 relative to all other conditions. Inhibition with a function blocking antibody 
suggested that this effect was IL-8 dependent. (D) Colorimetric analysis of Ca-release indicates that IL-8 
neutralization in media collected from biomineral-containing tumor models (BM+Ab) results in a much 
more pronounced decrease in osteoclast activity as compared to media collected from blank scaffold 
cultures (Blank+Ab). (E) Micrographs of osteoclast-mediated pit formation on bone mineral surface in 
the presence of conditioned media from biomineral-containing tumor models with and without anti-IL-8 
antibody. Scale bars represent 200 m. (F) Quantification of pit formation in response to the different 
media in the presence and absence of functional IL-8 signaling. 
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2.4 Discussion  
By integrating biomaterials and tissue engineering strategies, we have developed a novel, 
mineral-containing 3-D tumor model and have employed this culture system to systematically 
investigate the pro-metastatic role of HA under pathologically relevant conditions in vitro. The 
results of our study indicate for the first time that HA controls critical aspects of breast cancer 
bone metastasis by directing mammary tumor cells towards a phenotype that promotes secondary 
tumor growth and bone destruction via up-regulation of IL-8.  
Our data suggest that cellular interactions with HA are involved in the colonization and 
proliferation of breast cancer cells within the bone microenvironment and that RGD-containing 
fibronectin plays a role in this process. This possible relationship is supported by previous 
studies, which showed that stromal cell adhesion to HA is mediated by RGD-containing proteins 
(83, 84) and that a truncated version of fibronectin can block breast cancer growth and metastasis 
in vivo (85). Accordingly, HA promoted tumor tissue formation within the biomimetic tumor 
models in our studies and this effect was likely due to the integrated effects of increased 
adhesion and proliferation. Typically, secondary tumor formation within the bone 
microenvironment is considered a function of bone resorption because the degrading bone 
mineral matrix releases bioactive ions and growth factors critical to the proliferation of both 
normal and transformed cells (4, 86-88). Our data now suggests that not only soluble, but also 
insoluble cues inherent to the inorganic component of the bone mineral matrix regulate the 
metastatic growth of breast cancer cells within bone.  
Tumor-derived soluble factors shift the balance between bone formation and bone 
degradation towards osteolysis (1, 4, 18, 51, 66, 86, 87), and our results indicate that HA is 
strongly implicated in this process. More specifically, pre-osteoclast motility, osteoclast 
31 
differentiation, and osteoclast activity were all increased in response to conditioned media 
collected from mineral-containing tumor models relative to non-mineral-containing tumor 
models. To identify a potential molecular mediator that may be involved in these effects, we 
investigated the secretion of a number of growth factors and cytokines that are pivotal to bone 
metastasis. While VEGF and PTHrP, critical regulators of tumor angiogenesis (44, 89) and 
osteoclast resorption (1, 86, 87), respectively, were not affected by the presence of HA, IL-8 was 
up-regulated under these conditions. IL-8 promotes tumorigenesis through inflammatory and 
pro-angiogenic effects, but increasing evidence additionally implicates IL-8 as a pro-osteoclastic 
factor (51, 66, 90). Our data supports this concept and additionally suggests that HA increases 
the pro-osteolytic secretion of IL-8. In our studies, there was no significant difference in the 
number of differentiated osteoclasts in culture media collected from the mineral-containing 
tumor models relative to media supplemented with RANKL. However, conditioned media 
collected from HA-containing scaffold cultures induced higher resorptive activities of 
osteoclasts, and these effects may be due to the activation of IL-8 related signaling pathways that 
may play a role in ruffled-border formation and subsequent bone degradation (91, 92). While in 
the present study, we have identified that the osteoclastogenic signaling of IL-8 is regulated by 
HA, it should be further noted that cancer cell expression of other bone proteins may also be 
affected by the presence of bone mineral. For example, osteopontin and osteocalcin are 
expressed by breast cancer cells, are involved in bone cell signaling, and have a strong affinity 
for HA (32, 84, 93-95). 
A variety of mechanisms may be involved by which HA mediates the pro-metastatic 
effects noted in our studies. Differences in protein adsorption may support the initial colonization 
of tumor cells extravasated from blood vessels into the bone microenvironment. Changes in 
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protein adsorption may, in turn, alter the engagement of integrins, which is implicated in IL-8 
dependent tumor growth (44). Differences in cell signaling may thereby not only be related to 
quantitative differences in protein adsorption as detected in our studies, but also to 
conformational changes associated with HA-protein interactions (96). Additionally, HA confers 
the bone ECM with enhanced mechanical stiffness, and differences in tissue stiffness play a role 
in regulating tumor cell phenotype (97). However, in our studies the inherent bioactivity of HA, 
and not enhanced substrate stiffness, was responsible for our data. It has to be noted that these 
results do not exclude the possibility that mechanical stiffness influences bone metastasis over a 
different range of elastic moduli. Finally, the presence of HA may induce enhanced extracellular 
Ca
2+
 concentrations, a cue known to affect cancer cell behavior (98). However, HA is not highly 
soluble in the absence of strongly acidic conditions, which were not detected in our studies, and 
atomic absorption confirmed that Ca
2+ 
release from mineral-containing scaffolds was negligible. 
Accordingly, no enhanced Ca
2+ 
concentrations were detected in the respective culture media. 
Tissue engineering strategies can be invaluable in meeting the increasing demand for 
more physiologically-relevant models of bone metastasis in the future. In this study, we have 
utilized polymeric scaffolds that incorporated HA in the absence of bone cells and were able to 
specifically test the role of HA in breast cancer bone metastasis without confounding effects 
mediated by other cell-derived factors. By increasing the complexity of this culture model 
through, for example, incorporation of stromal cells inherent to the bone microenvironment (e.g., 
osteoblasts) (99, 100) or biologically inspired release of growth factors (101) the developed 
tumor model may become much more broadly applicable and may revolutionize in vitro studies 
of metastatic tumor cell interactions with bone. Finally, it should be noted that although in the 
current study we have investigated metastases with predominantly osteolytic characteristics, it 
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remains possible to use the mineral-containing scaffold system to model metastases with 
osteoblastic potential (e.g., prostate cancer) as well (1, 64, 72, 86). 
In conclusion, HA induces secondary tumor growth and IL-8 secretion by breast cancer 
cells, providing a molecular mechanism by which the mineral matrix of the bone 
microenvironment regulates the pathological bone remodeling associated with breast cancer bone 
metastasis. Directly targeting HA as an integral component of the bone mineral matrix may not 
represent a viable option for therapy. However, tissue-engineered tumor models will enable 
studies that will lead to an improved understanding of the molecular mechanisms by which HA 
mediates its pro-metastatic effects. This information will be critical to the identification of novel 
and specific therapeutic targets that will permit the improved therapy of patients with advanced 
breast cancer.  
2.5 Materials and Methods 
2.5.1 Cell Culture 
Human MDA-MB231 (44, 65, 86, 102) and MCF-7 (67, 79, 86) breast cancer cells 
(ATCC), and murine monocytic RAW 264.7 (103-105)cells (ATCC) were routinely maintained 
in complete DMEM (cDMEM) (i.e., DMEM (Invitrogen) supplemented with 10% fetal bovine 
serum [FBS, from Tissue Culture Biologicals] and 1% penicillin/streptomycin [PS, from 
Invitrogen]), under standard cell culture conditions (37°C, 5% CO2).  
2.5.2 Scaffold Fabrication  
Porous mineral-containing scaffolds, composed of poly(lactide-co-glycolide) (PLG) and 
hydroxyapatite (HA), were fabricated by a modified gas forming/particulate leaching method 
(60). Briefly, scaffolds were prepared with PLG particles (Lakeshore Biomaterials; average 
diameter = 250 μm), PLG microspheres (formed through a double emulsion process, average 
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diameter = 5 – 50 μm), HA particles (Sigma, average diameter of 200 nm confirmed with 
transmission electron microscopy), and sodium chloride particles (sieved to a diameter of 250-
400 μm, J.T. Baker). A total of 8 mg of polymer, 8 mg of HA nanoparticles, and 152 mg of NaCl 
was used and resulted in final scaffold dimensions of 8.5 mm diameter by 1 mm thickness after 
cold-pressing with a Carver Press (Fred S. Carver). Following high-pressure immersion in 
carbon dioxide gas and polymer foaming in a non-stirred pressure vessel (Parr Instruments), the 
scaffolds were leached in de-ionized water for 24 hours to remove NaCl porogen particles. Non-
mineral-containing PLG scaffolds, which were HA-free, were also fabricated, as were mineral-
containing scaffolds with varying amounts of HA (1:2, 1:4, 2:1 mass ratio with PLG). Prior to 
cell culture, scaffolds were sterilized by submersion in 70% ethanol for 30 minutes followed by 5 
washes in sterile PBS. 
2.5.3 Scaffold Characterization 
Scanning electron microscopy (SEM) (Leica 440) and light microscopy (Observer.Z1, 
Zeiss) were used to characterize the microarchitecture and porosity of scaffolds. Energy 
dispersive spectroscopy (EDS) (Leica 440) was employed to provide elemental analysis of 
scaffolds, including determination of surface presentation of HA in mineral-containing scaffolds. 
For SEM and EDS, scaffolds were sputter-coated with gold-palladium to reduce surface charge 
buildup (Denton Desk II). Scaffolds were tested with MicroCT (GE Healthcare, eXplore CT120) 
for further microarchitectural analysis and to ensure uniform distribution of HA in mineral-
containing scaffolds. Dynamic mechanical analysis (TA Instruments Q800) was used to 
determine the compressive moduli of the scaffolds. 
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2.5.4 Western Blot Analysis 
Unseeded scaffolds were incubated in cDMEM for 30 minutes, allowing serum proteins 
to adsorb. Subsequently, the adsorbed proteins were released from the scaffolds by mechanically 
disintegrating the polymer matrices in a solution of RIPA buffer (Sigma), protease inhibitor 
cocktail (Sigma), and PMSF (Sigma). Following centrifugation, the resulting scaffold lysates 
were resolved by SDS-PAGE and were blotted onto a PVDF membrane (BioRad). The 
membrane was incubated overnight with a rabbit anti-human fibronectin (Sigma) antibody. The 
membrane was then washed and incubated with a species-specific HRP-conjugated secondary 
antibody (Novus Biologicals), followed by ECL detection (Amersham Biosciences). 
2.5.5 Development and Characterization of 3-D Mineral-containing Tumor Models  
1.5 million MDA-MB231 or MCF-7 cells suspended in 30 L cDMEM were seeded into 
each scaffold and maintained under dynamic culture conditions on an orbital shaker at 37°C and 
5% CO2 for up to 10 days. Live/Dead assay was performed with calcein/propidium iodide 
(Invitrogen) staining and visualization on an Epi-fluorescence microscope (Observer.Z1, Zeiss). 
Cell adhesion was determined by quantifying the number of non-adhered cells 30 min after 
scaffold seeding using a cell counter (Beckman-Coulter). Blockade of RGD-binding integrins 
was performed by incubating the cells with 20 μg/mL of soluble RGD (Sigma) for 30 min prior 
to seeding. To measure cell proliferation, tumor cell-seeded constructs were washed in PBS and 
lysed in Caron’s buffer by sonication. Following centrifugation the DNA content in the 
supernatant was quantified through fluorescent Hoechst Assay (Invitrogen). For histological 
analysis tumor constructs were fixed in 10% formaldehyde and embedded in paraffin for 
sectioning and staining (H&E, von Kossa) according to established protocols.  
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2.5.6 Analysis of Conditioned Media 
Prior to each time point, breast cancer cell seeded-scaffolds were transferred to fresh 
culture plates, and media was changed to DMEM/1% FBS. Conditioned media were harvested 
after 24 hours for analysis. VEGF and IL-8 ELISAs (R&D) were performed on these samples 
according to manufacturer’s instructions, while PTHrP secretion was measured using a two-site 
immunoradiometric assay (Beckman Coulter). Protein secretion was normalized to DNA content 
as determined by fluorimetric Hoechst Assay. Scaffold-conditioned control media (i.e. media 
incubated with unseeded scaffolds) was also analyzed for calcium and phosphate ion 
concentration by atomic absorption. 
2.5.7 Osteoclastogenic Response 
2.5.7.1 TRAP Stain 
RAW 264.7 monocytes were seeded in tissue culture plates and cultured in tumor-
conditioned media collected from mineral-containing and non-mineral-containing 3-D tumor 
models for 5 days with or without 10 μg/mL of IL-8 neutralizing antibody (R&D). cDMEM and 
scaffold-conditioned control media (i.e. media incubated with unseeded scaffolds) were used as a 
negative controls, while cDMEM supplemented with RANKL (Sigma) served as a positive 
control (106). RANKL was added at a concentration of 50 ng/mL, which has previously been 
shown to induce osteoclastogenesis (66). To quantify osteoclastogenesis, a tartrate-resistant acid 
phosphatase (TRAP) staining kit (Sigma) was used according to manufacturer’s instructions in 
conjunction with image analysis of TRAP positive, multinucleated cells using AxioVision 
software (Zeiss). Similar cell numbers between the different experimental conditions were 
verified with an AlamarBlue assay (AbD Serotec Ltd) as indicated by the manufacturer.  
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2.5.7.2 Migration Assay  
RAW 264.7 monocytes were seeded on top of collagen-coated polycarbonate tissue 
culture inserts (8 m pore diameter, Nunc), which were placed into well plates with tumor-
conditioned media or control media as specified above. After 8h of incubation, a cotton swab 
was used to remove cells from the top of the inserts, while cells that had migrated through the 
polycarbonate membrane towards the conditioned media, were stained with DAPI. Stained 
inserts were then imaged, and the number of migrated cells was analyzed by AxioVision (Zeiss) 
image analysis.  
2.5.7.3 Osteoclast Activity Assays 
RAW 264.7 monocytes were seeded onto Corning Bone Cell Assay Surfaces (81)(kindly 
provided by Corning Life Sciences) and cultured in the culture media specified above. Osteoclast 
activity was determined by quantifying calcium release from the Bone Cell Assay Surfaces into 
culture media due to osteoclast-mediated resorption. Specifically, calcium release was measured 
by colorimetric detection of complexation of free calcium ions to o-cresolphthalein complexone 
(Sigma). Additionally, osteoclast activity was determined by light microscopic quantification of 
resorption pit area on the Bone Cell Assay Surface plates.  
2.5.8 Statistical Analysis 
One-way ANOVA and Student’s t-test were used to determine statistical significance, 
and p < 0.05 is indicated by (*) while p < 0.01 is indicated by (**) in all figures. For all 
experiments, sample size is greater than or equal to 3 for each condition. Data are presented as 
average; error bars indicate standard deviation. 
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CHAPTER 3:  HA DRIVES BONE METASTASIS BY INCREASING IL-8 SECRETION TO 
ACTIVATE SDF-1/CXCR4 METASTATIC AXIS 
3.1 Contributors 
Frank He performed 3-D culture of MDA-MB231 and the MCF-10A line cells in 
scaffolds for this study. He also harvested these samples and measured gene expression and IL-8 
secretion. Angela Du measured DNA from similar samples. MCF-10A and associated lines were 
used in collaboration with Dr. Scott Coonrad’s lab. Conditioned media studies with hMSCs were 
performed by Chris Patuwo, who also quantified SDF-1 secretion for these experiments Angela 
Du also performed all cryosections for this chapter, both scaffold samples and human tissue 
samples. She also assisted in CXCR4 immunostaining and Western Blotting on scaffold samples. 
Sunish Mohanan provided pathological diagnosis for human sections stained for IL-8. Drs. Cliff 
Hudis and Patrick Morris provided human samples from Memorial Sloan Kettering Cancer 
Center and their accompanying pathological and radiological diagnoses. I performed all other 
experiments and conceived of experimental design with Dr. Claudia Fischbach.  
3.2 Introduction 
It is currently estimated that up to 50% of breast cancers are associated with 
microcalcifications (23). While the presence of microcalcifications was first observed nearly 100 
years ago, the number of breast cancers that are diagnosed through screening mammograms that 
reveal mineral crystals in the breast continues to increase today (107). Mammography is thought 
to increase the odds of early detection, and this is important due the stark drop off in survival 
rates (from >90% to <25%) for tumors that are not diagnosed prior to the onset of initial 
metastasis (9).  
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 Despite their value as diagnostic markers, the relation between microcalcifications and 
disease progression remains unclear. Firstly, even when microcalcifications are found, they are 
most frequently not found to be associated with malignant disease (24). Though the reasons for 
this are not entirely clear, it is worth noting that ectopic calcifications are a common feature of 
other minor diseases and aging in general. It is also now known that differences in the chemical 
composition of microcalcifications are correlated with differences in invasiveness. Specifically, 
only breast calcifications that are composed of bona fide hydroxyapatite (HA) tend to be 
associated with invasive metastases (24, 27). Secondly, the interaction between HA at 
microcalcifications and breast cancer cells remains unclear. Currently, microcalcifications are 
treated strictly as passive indicators of cancer. However, in vitro data has shown that HA is 
bioactive and has pronounced effects on breast cancer cell behavior (24, 63, 108).While 
correlation with patient data is limited thus far, these findings in conjunction with clinical 
observations of calcification composition strongly suggest that HA microcalcifications may 
actively influence and even direct tumor progression and potentially metastasis. 
An overwhelming majority of late stage breast cancers metastasize to bone (1, 52). Bone 
metastases are associated with a number of debilitating symptoms including pain, susceptibility 
to fracture, and hypercalcaemia (64). The particular avidity to colonize in bone for metastatic 
breast cancer is well-known, but the specific mediators of this process remain not entirely clear. 
The long-established seed and soil theory proposes that sites of metastases are fundamentally 
similar to the primary tumor tissue in some way (1). In this context, it is possible that the 
appearance of microcalcifications, and specifically the bone-like mineral HA, prime breast 
cancer cells to metastasize specifically to bone. This thought is supported by studies showing 
that ductal carcinomas in situ (DCIS) that become invasive tend to display mammographic 
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microcalcifications (109). In understanding the molecular players that might be involved, past 
work has highlighted the existence of a “bone metastasis signature”. Elevated expression of this 
set of 5 genes (matrix metalloproteinase-1 [MMP1], osteopontin [OPN], chemokine CXC 
receptor-4 [CXCR4], connective tissue growth factor [CTGF], and interleukin-11 [IL11]) (18, 
110) is highly correlated with metastasis to bone. Studies have shown that within tumors, there is 
heterogeneous expression of the bone metastasis gene signature, but the mechanistic origin of the 
signature is unknown. We hypothesize that microenvironmental features such as calcifications 
might play a role in inducing enhanced expression of the bone metastasis signature.  
Beyond expression of these 5 genes, cytokine signaling networks are expected to play a 
role in metastagenicity (111, 112). Specifically, tumor-derived interleukin-8 (IL-8) may be 
involved in driving metastasis to bone. Elevated plasma levels of IL-8 have been correlated with 
increased prevalence of bone metastasis clinically (113, 114). Further, specific inhibition of IL-8 
has blocked tumor growth in xenograft models (115). There is also evidence to suggest that IL-8 
may be specifically upregulated in the presence of mineral (63, 108), a mechanism that could be 
related to physiological interactions between microcalcifications and developing mammary 
tumor cells. Soluble factors in the bone microenvironment may also be critical. Stromal-derived 
factor-1 (SDF-1) is known to be enriched in marrow compartment of bone, and it has also been 
shown to function as a chemoattractant for cancer cells through the surface receptor CXCR4 
(116, 117). The establishment of a pre-metastatic niche has been thought to be an initial 
prerequisite to support metastatic colonization (49), and upregulation of SDF-1 in the bone could 
feasibly be a part of this process. Emerging data suggests that IL-8 may actually induce increased 
SDF-1 secretion from stromal cells found in the bone or sensitize the SDF-1/CXCR4 axis by 
promoting CXCR4 surface expression (57, 118). Taken together, these data strongly suggest that 
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the interplay between microcalcifications, tumor-derived IL-8, and SDF-1 in bone marrow 
mediates breast cancer metastasis to bone. 
Three-dimensional (3-D) tissue culture has been used to create in vitro tumor models that 
recapitulate microenvironmental conditions much more accurately than conventional two-
dimensional cultures (119, 120). Within fabricated 3-D scaffolds, cancer cells organize 
themselves into tumor-like structures and have been shown to exhibit behavior reflective of in 
vivo conditions (79, 121). 3-D scaffolds have also proven to be useful in presenting mineral, such 
as HA, to cells, as they allow direct cell-mineral interaction (60, 63, 108). Previous scaffold 
systems have provided fundamental insight on how cells might target bone and respond to the 
bone microenvironment (100, 122). However, mineral in scaffolds is actually extremely well-
suited to the study of cell-microcalification interactions. We therefore used an engineered 
mineral-containing scaffold that had previously been confirmed to allow cell-mineral interactions 
(63) to investigate how cancer cell behavior may be regulated by HA and how this may affect 
migration towards bone. Our findings suggest that microcalcifications may direct tumor cell 
colonization of bone by providing a microenvironmental trigger that alters gene expression and 
regulates metastasis via the SDF-1/CXCR4 axis. 
3.3 Materials and Methods 
3.3.1 Scaffold Fabrication 
Scaffolds were created as previously described (60, 123). For mineral-containing (MIN) 
scaffolds (124), poly(lactide-co-glycolide (PLG) particles (Lakeshore Biomaterials, ground and 
sieved, average diameter 250 µm) and PLG microspheres (formed through double emulsion 
process, 5-50 µm diameter) were dry-mixed with nanocrystalline hydroxyapatite (Sigma) and 
porogenic NaCl (J.T. Baker, sieved, average diameter 250-400 µm). The mixture was then 
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pressed using a dye press (Fred S. Carver). The resulting matrices (8.5 mm diameter, 1 mm 
thickness) were pressurized in carbon dioxide (800 psi) in a non-stirred vessel (Parr Instruments 
4677). Following de-pressurization to allow polymer foaming, scaffold were soaked for 24 hours 
in DI water to leach out the salt. Non-mineral-containing (125) scaffolds (NM) were fabricated 
similarly, excluding the hydroxyapatite in the starting mixture. For characterization of 
mineralization, scaffolds were soaked in Alizarin Red (20%) and then washed 4 times in PBS. 
To observe general cell morphology upon seeding, scaffolds were fixed in 10% formalin, 
embedded in paraffin blocks, cut in cross section, and stained with hematoxylin and eosin (H&E) 
or von Kossa for visualization of tissue formation and cell association with mineral. Mineral-
containing scaffolds were decalcified prior to sectioning.  
3.3.2 Cell Culture  
MDA-MB231 human mammary tumor cells (ATCC), bone-metastatic (2287), and lung-
metastatic (4175) MDA-MB231 subpopulations (kindly provided by Dr. Joan Massague), MCF-
10A cells and derivative lines (62) (used in collaboration with Dr. Scott Coonrod), and human 
mesenchymal stem cells (hMSCs, Lonza) were maintained under standard culture conditions 
(37°C, 5% CO2). Complete DMEM (10% FBS [Tissue Culture Biologics], 1% PS [Gibco]) was 
used to culture MDA-MB231, Lonza MSCBM with SingleQuots was used for hMSCs, and 
DMEM/F12 (5% Horse serum [Invitrogen], 1 % PS, 100 ng/mL Cholera toxin [Sigma], 20 
ng/mL EGF [Millipore], 0.5 µg/mL Hydrocortisone [Sigma], 10 µg/mL Insulin [Sigma]) was 
used for the culture of MCF10A-derived series of cells. 
For 3-D culture, MIN and NM scaffolds were sterilized in 70% ethanol for 30 minutes. 
The NM scaffolds were used as controls in all studies to specifically examine effects mediated 
by presence of HA. After sterilization, scaffolds were subsequently washed 5X in sterile PBS, 
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and then soaked in culture medium for 30 minutes at 37°C to allow adhesive protein adsorption. 
Following incubation in medium, scaffolds were transferred to fresh culture plates, and 1.5 X 10
6
 
MDA-MB231 cells were statically seeded on top. 3-D cultures were maintained under standard 
culture conditions on an orbital shaker for up to 10 days. Adhesion was measured by harvesting 
scaffolds 30 minutes after seeding, while other time points were used for analysis of protein 
secretions (3 days), gene expression (10 days), and pre-culture for intracardiac injections (10 
days).  
3.3.3 Analysis of Bone Metastatic Gene Signature 
For analysis of gene expression, scaffolds were harvested after 10 days in culture. RNA 
was collected by degrading tumor cell-seeded scaffolds in TRIzol® (Invitrogen) and then 
extracting total RNA according to manufacturer protocol. Total RNA (1 μg) was reverse 
transcribed to cDNA (High Capacity cDNA Reverse Transcription Kit with random hexamers 
[(Applied Biosystems)]), and subjected to real-time RT-PCR (25 ng template, run in triplicate) 
using SYBR green detection (Quanta) on an Applied Biosystems 7500 System. All primer 
sequences were synthesized by IDT Technologies , and β-actin was used as an endogenous 
loading control gene. The following sequences were used: human IL-8 (fwd: 5’-
agaaaccaccggaaggaaccatct-3’, rev: 5’-agagctgcagaaatcaggaaggct-3’), human OPN (fwd: 5'- 
agttctgaggaaaagcagc-3', rev: 5'-cccctaccggaacatacg-3'), human MMP1 (fwd: 5’-
aatgcaggaattctttggg, rev: atggtccacatctgctcttg-3’), human IL11 (fwd: 5’-
agatatcctgacattggccaggca-3’, rev: 5’-acttcagtgatccactcgcttcgt-3’), human CXCR4 (fwd: 5’-
agggaactgaacattccagagcgt-3’, rev: 5’-aaacgttccacgggaatggagag-3’), human IL13Rα2 (fwd: 5’-
acggaatttggagtgagtgg-3’, rev: 5’-tggtagccagaaacgtagca-3’), human MMP2 (fwd: 5’-
gcggcggtcacagctactt, rev: 5’-cacgctcttcagactttggttct-3’), and human β-actin (fwd: 5’-
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aatgtggccgaggactttgattgc-3’, rev: 5’-aggatggcaagggacttcctgtaa-3’)  For quantitative analysis, the 
previously developed ΔΔCt method was employed (126). 
3.3.4 Collection of Conditioned Media 
3-D cultures were used to generated conditioned media. After 2 days in culture, scaffolds 
were transferred to fresh culture plates to eliminate the influence of cells that had initially 
adhered to the culture plate during seeding. Concurrently, culture medium was refreshed with 
serum-depleted medium (1% serum). After 24 hours, media was harvested. First, it was 
centrifuged at 4000 rpm for 10 minutes, and the supernatant was collected to eliminate any 
cellular debris. Subsequently, it was concentrated to 10X using a centrifugal concentrator with 5 
kDa molecular weight cutoff (Millipore). To directly compare the effects of soluble factors 
between NM and MIN scaffold cultures, conditioned media was normalized to cell number by 
diluting in fresh serum-depleted media. 10X conditioned medium was stored at -20 prior to use 
in culture. The medium was then re-diluted with fresh basal medium to a final concentration of 
2X for use as culture medium. 
3.3.5 Luciferase Labeling 
Cells were labeled with luciferase using the Cignal Lenti Reporter system (Qiagen). 
MDA-MB231 cells and subpopulations were plated in minimal medium and allowed to adhere 
overnight. Lentivirus was added to cells according to manufacturer’s instructions to stably 
induce luciferase expression. After 16 hours, lentivirus was removed, and cells were refreshed 
with basal media. Cells were then fed puromycin (puromycin.com) for selection of positively 
transduced cells. Puromycin was given every 3 days for one week at 0.5 µg/mL in basal media. 
Following selection, cells were maintained again under standard conditions. 
3.3.6 SDF-1 and IL-8 ELISA 
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To quantify secretion of IL-8 by breast cancer cells in 3-D, seeded-scaffolds were 
transferred to fresh culture plates, and media was changed to DMEM/1% FBS 24 hours prior to 
collection of media. Upon collection, IL-8 ELISA (R&D) was performed on these samples 
according to manufacturer’s instructions. When media was harvested, scaffolds were lysed in 
Caron’s Buffer and sonicated to liberate DNA. Total DNA content was measured from these 
samples by Quantifluor assay according to manufacturer instructions (Invitrogen). For hMSC 
secretion of SDF-1, a 2-D culture of hMSCs was pre-treated with conditioned media from tumor-
cell seeded scaffolds for 24 hours. Next, media was refreshed to hMSC basal media. 24 hours 
after this, hMSC media was collected for SDF-1 analysis. SDF-1 ELISA was used (R&D 
systems) according to manufacturer instructions, and secretion was normalized to cell number as 
assessed by hemacytometer.  
3.3.7 Transwell Migration Assay 
Migration assays were performed using a transwell (8.0 µm pores, BD Falcon 
fluoroblock) in a 24-well culture plate. Prior to assay, transwells were coated with collagen I 
(Gibco) on one side by soaking. In all assays, the bottom chamber either contained 5 X 10
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plated hMSCs or 0.5 ng/mL SDF-1 (R&D Systems). The top chamber was seeded with 5 X 10
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cells, and migration took place over 8 hours, after which time transwells were fixed in formalin 
and stained with DAPI. DAPI stained images were analyzed manually to determine cells per 
field with 20X objective. For each well, at least 5 fields were analyzed. Fields were selected 
away from the edges of the wells to avoid autofluorescent interference. For each condition, at 
least 3 wells were quantified, and all migration graphs represent an overall pooled average of 
counts from all wells. For inhibition studies, cells in the top chamber were pre-incubated with 25 
µg/mL of anti-CXCR4 (R&D Systems) to inhibit the migratory receptor prior to seeding. 
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Alternatively, 150 µg/mL of anti-SDF-1 or 10 µg/mL of anti-IL-8 (R&D Systems) was added to 
the bottom chamber to inhibit molecules in solution. 
3.3.8 CXCR4 Western Blot 
Lysates from 3-D scaffold cultures were collected in 300 µL RIPA buffer (Sigma) with 
protease/phosphatase inhibitors (Sigma) and PMSF (Calibochem) per sample. Scaffolds were 
mechanically chopped in buffer followed by sonication. The samples were then pelleted via 
microcentrifuge and the supernatant collected for Western Blot analysis. Protein concentrations 
were determined by bicinchoninic acid proteins assay (Thermo Scientific), and equal amounts 
were loaded into the gel. Proteins were separated by SDS/PAGE and transferred to a PVDF 
membrane (bio-rad). The membrane was incubated overnight at 4°C with primary antibodies 
against GAPDH (0.1 µg/mL, Sigma) and CXCR4 (2 µg/mL, Abcam), followed by 1 hr 
incubation with HRP-conjugated anti-rabbit secondary antibody (Novus Bio) and HRP-
conjugated anti-mouse secondary antibody (Millipore) at room temperature. Chemiluminescence 
detection was performed to visualize the protein using an ECL kit (Thermo Scientific). ImageJ 
software was used in gel analysis mode to quantify differences in observed bands.  
3.3.9 Animal Studies  
All work was performed in accordance with standards set by the Cornell University 
Institution Animal Care and Use Committee. BALB/C-nu nude mice (Taconic Farms) were used 
for all studies.  
For intracardiac injection, luciferase-labeled cells were prepared by pre-culture in 
scaffolds for 10 days. Prior to injection, cells were trypsinized for removal from scaffolds, and 
suspended in PBS at a concentration of 10
6
/mL. 100 µl of the suspension was injected into the 
left-ventricle of 4-week old mice. After injection, mice were imaged by bioluminescence under 
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isoflurane weekly for up to 12 weeks. Upon euthanasia, blood, tumors, lungs, and bones were 
harvested for ex vivo analysis. Tumors were divided for collection of lysates in T-PER buffer 
(pierce) and formalin-fixation/paraffin-embedding. Bones and lungs were collected in formalin 
for paraffin embedding. Blood was collected via cardiac puncture and immediately added to ice 
cold EDTA at 1 mL blood per 50 µL EDTA in a microcentrifuge tube. The tube was inverted 
and kept on ice prior to centrifugation, after which the plasma supernatant was collected and 
stored for analysis.  
For all studies, paraffin sections were stained with H&E and analyzed for 
characterization of malignant features using the ScanScope System and software (Aperio). H&E 
sections of bone were analyzed for trabecular thickness and bone volume fraction by measuring 
dimensions of trabeculae with the ScanScope software. Lysates were analyzed for IL-8 and 
plasma for SDF-1 by ELISA (R&D Sytems DuoSet) according to manufacturer’s instructions.   
3.3.10 Bioluminescent Imaging (BLI) 
Mice were injected intraperitoneally with Luciferin (Gold Biotechnology) (150 mg/kg) 5 
minutes prior to imaging. On-board isoflurane (2%) was used during imaging in the system 
(Xenogen IVIS-200 ). Settings and analysis were controlled via the accompanying software 
(Living Image). All luminescence scales are reported in photons/second/square cm/steradian 
(p/sec/cm
2
/sr).  
3.3.11 Cryosectioning and Immunostaining 
Scaffold cultures were washed with cold PBS and then fixed in 4% paraformaldehyde. 
After fixation, scaffolds were soaked in 20% sucrose at 4°C overnight to prevent crystal 
formation during freezing and subsequently mounted in OCT (Bio-Tek). Tissue samples were 
provided as frozen blocks on transfer from Memorial-Sloan Kettering. Frozen blocks were 
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cryosectioned to 12 µm thickness and mounted on pre-cleaned glass slides. Prior to staining, 
sections were baked for 20 minutes at 65°C and re-hydrated in Tris-buffer. For IL-8 
immunohistochemsitry (IHC), sections were then blocked with 3% hydrogen peroxide to prevent 
signal interference from endogenous activity. Antigen retrieval was performed with Proteinase K 
(Dako), and TNB solution (Perkin-Elmer) was used for blocking. Sections were incubated with 
primary antibody against IL-8 (5 µg/mL, R&D Systems) overnight at 4°C, followed by a 30 min 
incubation at room temperature with a biotinylated secondary antibody against mouse (Vector 
Labs). To increase signal, the TSA amplification kit (Perkin-Elmer) was used according to 
manufacturer’s direction. Signal detection was performed with DAB chromogen (Thermo 
Scientific), and sections were counter-stained with hematoxylin. Slides were then dehydrated via 
ethanol gradient and mounted with Entellan (Merck). Slides were scanned using the ScanScope 
System (Aperio) for imaging purposes. For CXCR4 immunofluorescence, antigen retrieval was 
performed in citrate buffer before sections were incubated with a primary antibody against 
CXCR4 (25 µg/mL, R&D Systems), followed by an AlexaFluor 647-conjugated anti-mouse 
secondary antibody (Invitrogen). For luciferase immunofluorescence, antigen retrieval was done 
through digestion with proteinase K for 10 minutes, and then sections were incubated with 
primary antibody against luciferase (1 µg/mL, Sigma), followed by an AlexaFluor 488-
conjugated antimouse secondary antidbody (Invitrogen). All immunofluorescence samples were 
counterstained with DAPI (Invitrogen) and mounted in ProLong Gold Antifade Reagent 
(Invitrogen). Fluorescence imaging was performed with a Confocal Microscope (Zeiss 710) or 
epi-fluorescence microscope (Zeiss Observer.Z1). 
3.3.12 Human Sample Analysis 
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16 patient samples overall were obtained for analysis. Scanned IHC images with IL-8 
stain were transferred to a pathologist for specific evaluation and diagnosis. Slides were scored 
for gross intensity of IL-8 staining, and individual acini and ductal structures were identified for 
each slide and scored according to ductal integrity/proliferative capacity as well as intensity of 
IL-8 stain.  Sections were comprehensively analyzed to identify all ductal structures, and all 
ductal structures in each section were included in analysis. If at least 3 ducts were not able to be 
indentified in a section, the section was not used in analysis All metrics were scored on a 0-3 
scale, with 0 representing negligible intensity or proliferation and 3 representing maximal 
staining or excessive proliferation and total deterioration of acinar architecture. This analysis was 
performed blind, without knowledge of radiology or pathology reports from consulting 
clinicians. After full evaluation was completed, IHC evaluation was compared with radiology 
and pathology notes and CXCR4 immunofluorescence results for final analysis. 
3.3.13 Statistical Analysis 
For figures, experiments were run independently in triplicate to verify trends. Graphs and 
images represent these trends. For all in vitro studies, experiments were run with sample number 
of 3 or 4. For in vivo work, groups of mice initially consisted of five mice, but groups of 3 or 4 
were also included in analysis in the case of unexpected animal death. Statistical analysis was 
performed in GraphPad Prism 5. Student’s t test or ANOVA with Tukey post-hoc analysis was 
used to establish statistical significance (p<0.05), and in all graphs, (*) indicates p < 0.05. All 
data are represented as average ± standard deviation.   
3.4 Results 
3.4.1 Cell-mineral interactions in scaffolds 
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Scaffolds were tested to ensure that they allowed direct interaction of HA with breast 
cancer cells. To test surface presence of mineral within scaffold pores, scaffolds were soaked in 
calcium-binding Alizarin Red. When compared to non-mineral-containing control scaffolds, the 
mineral-containing scaffolds showed strong absorption of the red stain, suggesting surface 
availability of HA (Fig.3.1A). Upon static seeding of scaffolds (shown schematically in Fig. 
3.1B), cross-sectional H& E staining showed that cells are able to adhere throughout the scaffold 
(Fig. 3.1C), and von Kossa staining showed that cells attach along mineral-containing surface 
(Fig. 3.1D). The adhesion of cells to HA is in agreement with our past findings, indicating that 
cells have >90% seeding efficiency in mineral-containing scaffolds, significantly enhanced 
relative to non-mineral-containing controls (63). 
3.4.2 Growth and IL-8 secretion by ductal carcinoma in situ (DCIS) cells in mineral-
containing scaffolds 
Our previous work has indicated that HA stimulates IL-8 secretion and growth in MDA-
MB231 cells (63). To understand if these changes in phenotype were a cell line specific 
phenomenon or if this trend holds for other transitioning or malignant cells, these effects were 
studied with MCF10A-DCIS cells. Similar behavior was observed for DCIS cells in mineral-
containing scaffolds. A DNA assay indicated that growth and adhesion are enhanced for these 
cells HA-containing constructs, with 50% more growth overall due to either cell division or 
induction of polyploidy, which could contribute to genetic instability (Fig. 3.2A). Additionally, 
ELISA analysis showed that DCIS cells also increased IL-8 secretion 3-fold in mineral-
containing scaffolds relative to non-mineral-containing controls (Fig. 3.2B). Interestingly, a 
similar increase in IL-8 secretion was observed for MCF10CA1A invasive carcinoma cells, but 
not for MCF10A normal mammary epithelial cells (Fig. 3.2B).  
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Figure 3.1: Gas foaming/particulate leaching for scaffold creation 
(A) Alizarin red calcium-binding stain shows that mineral-containing scaffolds present HA at surface for 
cellular availability. (B) Schematic showing that simple static seeding is used for scaffold prior to 
dynamic cell culture. (C) H&E stain indicating heterogeneity of cells in scaffold upon seeding. Scale bar 
represents 100 µm. (D) Von Kossa stain (mineral in black, cell nuclei in red) indicating that cells attach 
around mineral in scaffolds. Scale bar represents 50 µm. 
Non-mineralized Mineralized
3-D Scaffold
Static seeding of cells
(A)
(B)
(C) (D)
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Figure 3.2: Cellular response of MCF10A line of cells in scaffolds 
(A) DNA assay indicated that MCF10A-DCIS cell grow more in MIN scaffolds. (B) 
Tumorigenic MCF-10A cells (CAIA and DCIS) increase IL-8 secretion in MIN scaffolds 
according to ELISA. 
3.4.3 Bone metastasis signature in mineral-containing scaffolds 
To determine if expression of the bone metastasis gene signature might be related to the 
presence of HA, the transcription of these gene was investigated for cells cultured within 
scaffolds. It was found that the majority of the genes in the bone metastasis signature were 
upregulated in the presence of mineral for parental MDA-MB231 cells (Fig. 3.3A). These 
included OPN, CXCR4, and MMP1. Gene expression analysis also confirmed that IL8 mRNA 
levels increase in response to the presence of HA (Fig. 3.3A). Furthermore, when a lung-specific 
subpopulation of MDA-MB231 cells (4175LM) was cultured in mineral-containing scaffolds, 
expression of IL8, CXCR4, and OPN all increased (Fig. 3.3B). It was found that over time in 
mineral-containing culture, 4175LM expression of these genes approached levels found in an 
established bone-specific subpopulation of MDA-MB231 cells (2287BM). Conversely, 4175LM 
cells downregulated expression of CXCL1, IL13Rα2, and MMP2 (Fig. 3.3C), which are genes 
that have been identified as part of a lung metastasis gene signature (124). 
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Figure 3.3: Expression of tissue-tropic metastasis signatures in scaffolds 
(A) mRNA analysis shows that bone metastasis gene signature is partially enriched on mineral-containing 
scaffolds for general parental population of MDA-MB231 cells. (B) Mineral also “reprograms” cells, as it 
induces increased expression of these genes for cells that previously were directed to lung (4175 LM) and 
(C) decreases expression part of the lung metastasis gene signature. 
3.4.4 Effect of tumor-derived IL-8 on mesenchymal stem cells and tumor cell migration 
The functional effects of HA-regulated secretion of IL-8 were studied next. To 
understand the potential role IL-8 plays in paracrine or endocrine signaling, its effect on MSCs, 
the prevalent stromal cell type in bone, was explored. Culturing MSCs with tumor-conditioned 
media (TCM), it was initially found that tumor-derived soluble factors stimulated MSC secretion 
of SDF-1 (Fig. 3.4A). Furthermore, this response was enhanced for TCM from mineral-
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containing cultures (124) relative to non-mineral-containing cultures (125). Looking specifically 
at the role of IL-8 among the milieu of factors in TCM, SDF-1 secretion increase in response to 
purified IL-8 was similar to that provoked by TCM (Fig. 3.4B). Monoclonal antibody inhibition 
of IL-8, indicated that IL-8 in TCM did indeed underlie increased MSC secretion of SDF-1. 
Finally, by inhibiting MSC surface receptors to IL-8 (CXCR1 and CXCR2), it was determined 
that IL-8 based induction of SDF-1 happens via the CXCR1 receptor (Fig. 3.4B).  
SDF-1 is known to attract breast cancer cells via CXCR4, and the effects of TCM-
induced, MSC-derived SDF-1 on MDA-MB231 migration were next investigated using a 
transwell migration assay. The experimental setup is shown schematically in Fig. 3.5A. The 
transwell membrane allows soluble factor exchange and directed migration of MDA-MB231 
cells. When MSCs were first treated with IL-8, they strongly attracted MDA-MB231 cells 
relative to control conditions. However, when antibodies against SDF-1 or its cognate receptor 
CXCR4 were introduced into the setup, this effect was strongly attenuated (Fig. 3.5B). Since 
overall results indicated that HA-containing cultures did not just stimulate increased SDF-1 
secretion by MSCs, but also upregulation of CXCR4 for breast cancer cells (Fig. 3.3), the 
contribution of higher receptor concentration to migration was also explored. 
Immunofluorescence and Western blot analysis confirmed that both DCIS (data not shown) and 
MDA-MB231 cells in HA-containing scaffolds have more of the CXCR4 receptor (Fig. 3.6A). 
When cells were pre-conditioned in mineral-containing scaffolds prior to seeding in the 
transwell, they exhibited enhanced migration as well, and this effect was abolished by treatment 
with a monoclonal antibody against CXCR4 (Fig. 3.6B).  
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Figure 3.4: SDF-1 Secretion by MDA-MB231 cells in response to IL-8 
(A) Tumor conditioned media (TCM) stimulates SDF-1 secretion by mesenchymal stem cells (hMSCs), 
and media from mineral-containing scaffold cultures evokes larger response. (B) Inhibition studies with 
monoclonal antibodies suggest that IL-8 in TCM is responsible for induction of SDF-1 secretion via 
CXCR1 
 
Figure 3.5: Migratory response due to IL-8 stimulation of SDF-1/CXCR4 axis 
(A) Schematic of Transwell migration assay set up. (B) hMSCs treated with IL-8 produced strong 
migratory response from MDA-MB231 cells in a Transwell migration assay, and  inhibiting SDF-1 in 
media or its cognate receptor CXCR4 on tumor cell surface with antibodies attenuated this migratory 
response. 
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Figure 3.6: Modulation of CXCR4 levels by HA and effect on tumor cell migration 
(A) Immunofluorescence and Western Blot confirmed increased levels of CXCR4 protein in and on the 
surface of cells cultured in mineral-containing scaffolds. Scale bars represent 50 µm. (B) Cells that were 
pre-cultured in mineral-containing scaffolds displayed enhanced migratory capability relative to those 
cultured in non-mineral-containing scaffolds, and this effect was inhibited by anti-CXCR4.  
3.4.5 Changes in metastatic tropism in vivo due to exposure to HA 
Because significant gene expression changes were observed for MDA-MB231 cells in 
vitro, the functional consequences for in vivo behavior were next examined. 4175LM cells that 
had been pre-cultured in HA-containing scaffolds (4175MIN) were found to predominantly 
colonize bone, while 4175LM cells from control scaffolds (4175NM) maintained their original 
pattern of lung seeding, based on luminescent tracking of tumor cells (Fig. 3.7A-B). Histological 
analysis showed pleomorphism and osteolytic effects in bones of mice injected with 4175MIN, 
including trabecluar thinning and loss of trabeculae relative to control conditions (Fig. 3.7C). 
Further confirmation of cells from mineral-containing scaffolds was attained through anti-
luciferase staining for tumor cells (Fig. 3.8D). Histology and immunofluorescence also showed 
severe lung lesions only for mice injected with 4175NM (Fig. 3.9).  
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Figure 3.7: in vivo colonization of intracardailly injected MDA-MB231 4175LM cells pre-
conditioned in scaffolds 
(A) 4175 cells pre-conditioned in non-mineral-containing scaffolds (4175NM) colonize lungs, while those 
pre-conditioned in mineral-containing scaffolds (4175MIN) colonize bone as demonstrated by in vivo 
(A) 
4175 NM
(B) 
(C) 
(D) 
3 wks 5 wks 7 wks
4175 NM
4175 MIN
3 wks 5 wks 7 wks
4175 MIN
HI
4175 NM 4175 MIN
*
4175 NM 4175 MIN
Bone
LungLung
HI
LOLO
59 
bioluminescent tracking. Heat bars indicate radiance in photons/sec/cm
2
/sr. (B) ex vivo BLI shows 
positive signal indicative of tumor cell colonization in lungs of 4175NM and femur bone of 4175MIN-
injected mice (C) H&E sections of femur indicate potential thinning of trabeculae and neoplastic 
transformation. Green arrows indicate trabeculae and black arrows show pleomorphism that suggested 
transformation. Scale bars in “HI” magnification represent 100 µm and scale bars in “Lo” magnification 
represent 200 µm. Inset in panel four shows 20X magnification of pleomorphic cells. (D) Luciferase 
immunofluorescence on sections of bone indicate the presence of injected tumor cells. Positive stain is in 
green, while cell nuclei are counterstained with DAPI in blue. White arrows indicate cortical bone 
surfaces, while red star shows presence of positively stained cells invaded into bone. Scale bars represent 
100 µm.  
 
Figure 3.8: Quantification of osteolysis in intracardially injected mice 
Osteolysis was quantified by general decrease in number and thickness of trabeculae in mice as observed 
in H&E images. Images for quantification were sampled from proximal femur of mice. Representative 
images used for quantification are shown. Scale bars represent 500µm, and green boxes indicate 
trabeuclae that were sampled in analysis 
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Figure 3.9: Colonization of lung by intracardially injected MDA-MB231 cells pre-conditioned in 
scaffolds 
Low (top) and higher magnification (middle) images of H&E-stained lung sections of mice show 
aggressive colonization of lungs only for mice injected with cells pre-conditioned in non-mineral-
containing scaffolds. Black scale bars indicated 200µm. Luciferase immunofluorescence (bottom) shows 
positive staining in green, indicative of tumor cell colonization, also only for 4175NM. White Scale bars 
represent 100 µm. 
4175 NM 4175 MIN
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3.4.6 Preliminary correlations between ductal proliferation, presence of IL-8, and 
microcalcifications  
As in vitro data indicate a potentially crucial role for IL-8 in conjunction with 
microcalcifications, human tumor samples were analyzed histologically for both. Samples 
demonstrated variable staining patterns, with IL-8 present in ducts, stroma, or both (Fig. 3.10A). 
Within samples, it was observed that there was at least preliminary correlation between a 
pathological score of ductal proliferation and IL-8 levels within the corresponding duct (Fig. 
3.10B). Total tissue IL-8 levels were found to generally correlate with a pathology diagnosis of 
microcalcifications, as well as a radiology diagnosis of microcalcifications, but these findings 
were limited by a small sample size and few disease-free tissues included in the study. Finally, 
tissue samples were also fluorescently stained for CXCR4. Distribution of CXCR4 varied, also 
being identified as stromal or ductal. Overall, there were far more sections that did not stain at all 
for CXCR4 as compared to IL-8 (7/16 vs. 2/16).  Notably, sections that stained positive for 
CXCR4 were also sections observed to have the highest ductal IL-8 levels and were more likely 
to be from patients that had detectable microcalcifications according to mammography (Table 
3.1). Furthermore, sections with higher gross staining of IL-8 throughout tissue were largely 
associated with mammographic calcifications and positive CXCR4 immunofluorescence.   
62 
 
Figure 3.10: Immunostaining and pathology analysis of human mammary tissue sections 
(A) IL-8 IHC with hematoxylin counterstain. Red stars show observed ducts, and black arrows indicate 
areas of strong positive IL-8 stain. Scale bars represent 100 µm. (B) Ductal proliferation score correlated 
with pathologist diagnosis of IL-8 staining intensity per duct over all patient samples (no statistical 
significance) (C) CXCR4 immunofluorescencewith DAPI counterstain. Red star shows observed duct. 
Scale bars represent 200 µm. 
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Table 3.1 Correlational evaluation of parameters analyzed for human mammary tissue sections 
CXCR4 status was correlated with mammographic detection of calcification and high IL-8 staining; 
Moderate to high IL-8 staining was correlated with mammographic detection of calcification and 
CXCR4+ status 
3.5 Discussion 
As microcalcifications are one of the most salient markers and pertinent 
microenvironmental features in breast cancer (24, 27, 127), the understanding of mammary 
tumor biology would greatly benefit from mineral-containing culture systems that allow probing 
of cell-HA interactions. The use of tissue engineering principles to develop physiologically 
relevant material systems as culture models has provided new insight into cancer biology (79, 
122, 128), but few systems that recapitulate the interplay of mineral, cells, and soluble factors 
have been thoroughly explored. The role of HA as a bioactive and cell-instructive material has 
been highlighted (32, 129, 130), and our past work has generated basic knowledge on how gas-
foamed/particulate leached scaffolds can present mineral to cells and how cell behavior is 
regulated by HA (63, 108). Here, scaffold studies have been integrated with a molecular 
approach to provide a robust model describing how cytokine-based signaling drives metastasis 
under the influence of mineral. The data suggest that HA in the form of microcalcifications can 
Total
Calcifications  in 
Mammogram 
Ductal IL-8 
Score >3
CXCR4+ 9 6/9 3/9
CXCR4- 7 3/7 0/7
Total
Calcification in 
Mammogram
CXCR4+
Total IL-8 
Score >2
11 8/11 7/11
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bias breast cancer metastases to bone by activating the SDF-1/CXCR4 chemoattractant axis via 
increased secretion of IL-8. 
Screening mammograms are currently one of the most widespread tools for diagnosing 
breast cancer (23, 27). Presently, there is only limited evidence to suggest that 
microcalcifications detected in this manner can play an active role in promoting metastasis (131). 
However, the presence of HA and elevated level of proteins normally found in bone (31, 36) is in 
line with the theory that sites of metastases share tissue properties with primary tumor location 
(119, 132). Additionally, previous work indicates that HA can specifically induce enhanced 
secretion of various growth factors and cytokines in breast cancer cells (24, 63, 108). Our data 
here further implicate elevated secretion levels of these cytokines, specifically IL-8, in driving 
bone metastasis. A potentially crucial role in breast cancer metastasis for IL-8 is supported by 
other studies, which have shown that IL-8 is highly expressed by metastatic subpopulations of 
breast cancer cells (61, 113, 115, 133, 134) and that high IL-8 levels are observed clinically in 
bone metastasis patients (114, 135, 136). Additional studies have also shown that IL-8 can play a 
role in secondary processes that are required for metastasis, including angiogenesis (44, 137) and 
hypoxia response (79). Importantly, work with this scaffold system has shown that HA-regulated 
IL-8 secretion occurs for a number of breast cancer cell lines with varying molecular phenotypes, 
including MDA-MB231, MCF10A-DCIS, MCF10CA1A, and MCF-7 (63). Conversely, non-
transformed cell lines do not seem to respond to HA in the same way (Fig. 3.2C). From this, we 
can infer that microcalcifications may be pro-metastatic, but they do not seem to induce 
cancerous transformation on their own.  
Based on our findings, IL-8 may be involved in determining the skeletal tropism 
exhibited by breast cancer metastases. We have shown that IL-8 can stimulate stromal 
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production of SDF-1, and other studies have demonstrated that the SDF-1/CXCR4 axis is 
specifically activated for bone, but not lung, metastasis (55, 116, 117, 138). In fact, SDF-1 
gradients are known to be important in mobilizing homing of many cell types to bone marrow 
(49, 57, 139). Blockade of CXCR4 has been shown to prevent metastasis in past studies, and 
several CXCR4 inhibitors are in clinical trials currently (140, 141) We hypothesize that tumor-
derived IL-8 signals to stromal cells in the marrow compartment in an endocrine manner, 
initiating the formation of an SDF-1-rich pre-metastatic niche. Additionally, we have observed 
that HA stimulates enhanced surface receptor concentrations of CXCR4, thereby sensitizing 
breast cancer cells to the dramatically elevated levels of SDF-1. An endocrine mechanism is 
supported by past work on the establishment of pre-metastatic niches that suggests that the bone 
microenvironment is altered prior to cancer cell colonization (49, 56, 139). Moreover, clinical 
data shows that patients with bone metastasis have higher plasma concentrations of IL-8 (114, 
135), indicating that IL-8 is circulating and available to stromal cells in the marrow. While it is 
well-known that IL-8 is a key cytokine regulator of tumor cell behavior and malignant 
progression, our data show that it could be an important player in directing breast cancer 
metastasis to bone specifically. Along with the observation that IL-8 is potentially regulated by 
HA in the form of microcalcifications at the primary tumor, there is strong evidence to suggest a 
mechanistic model wherein microcalcifications promote metastasis to bone through a 
combination of IL-8 signaling and CXCR4 enrichment. 
Cancer genomics has shed much light on fundamental mechanisms underlying disease 
inception and progression. However, it is clear that microenvironmental cues may be crucial to 
understanding patterns of expression that are associated with malignancy. In the case of bone 
metastasis, the identification of the bone metastasis gene signature shows great promise for use 
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in cancer diagnostics and therapeutic intervention (11, 18). In this study, it was shown that 
microenvironmental HA may induce expression of the bone metastasis signature, and the 
functional consequences of upregulation of these genes in the context of metastatic disease was 
explored. Firstly, it was found that OPN, CXCR4, and MMP1 were consistently upregulated in 
response to HA for general populations of breast cancer cells (Fig. 3.3A). All of these genes 
produce proteins that are vital to the combination of enzymatic cleavage of ECM, motility, and 
chemotaxis that are required for metastasis to bone (117, 140, 142, 143). It is possible that in 
breast tumors, microcalcifications that form play a role in activating these genes, thereby being 
essential to drive bone metastasis. Interestingly, microcalcifications did not just upregulate these 
genes for heterogeneous populations of breast cancer cells, but they elicited similar response 
from 4175LM cells that had previously been established as 100% lung metastatic (Fig. 3.3B). 
This finding suggests that microenvironmental control may be paramount in defining tissue 
tropism of metastasis. Though initially assumed that genetic variation was a natural component 
of the heterogeneity of a tumor, it is possible that heterogeneous exposure to HA underlies 
initially differing affinities for specific tissues upon metastasis. In this case, once breast cancer 
cells that were initially conditioned in vivo in lung are cultured with HA, they revert or are “re-
programmed” to a bone-colonizing phenotype. This possibility is supported by in vivo data that 
shows bone colonization by 4175MIN cells. From a radiologic standpoint, microcalcification 
patterns that are classified as “aggressive” tend to have the highest surface areas and therefore 
the most exposure to cells (144), potentially explaining why these microcalcification patterns are 
associated with a more frequent occurrence of bone metastasis.  
Insights provided thus far from image analysis of patient samples is limited but somewhat 
illuminating. Qualitative assessment indicated that ductal proliferation showed reasonable 
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correlation with IL-8 levels in individual acinar structures. In some slides, largely visible 
microcalcifications were apparent, and in these cases dramatic IL-8 staining was observed. This 
preliminary data lacked sufficient sample size for establishment of statistical significance by 
traditional methods (Exact Fisher’s Test). Furthermore, unfortunately, specifically located 
microcalcifications could not be correlated with specific IL-8 staining, as tissues were 
heterogeneous structural identifications were made through H&E stains of separate pieces of 
tissue from the same patient. In the majority of cases, we found significant IL-8 staining in the 
stromal compartment of the tumor, indicating that support cells may also be producing 
substantial amounts of IL-8. This is not entirely unexpected, as previous work has shown that 
disease-associated cells in adipose tissue secrete significant levels of IL-8 (128, 145). 
Nonetheless, this finding illustrates the vastly increased complexity of physiological tumors that 
are interacting with a wide range of normal and co-opted cells. Data on CXCR4 was also 
promising, showing that CXCR4 expression within ducts was correlated with ductal 
microcalcifications found in mammograms. This result agrees with our in vitro data, and helps to 
provide validation for the scaffold system as an appropriate tumor microenvironment mimic.  
HA appears to facilitate signaling that promotes metastasis of breast cancer specifically to 
bone. By stimulating IL-8 secretion, which in turn induces enrichment of soluble SDF-1 in bone, 
and sensitizing breast cancer cells to SDF-1 by increasing expression of CXCR4, HA-containing 
microcalcifications are a pro-metastatic microenvironmental cue. All of the molecules discussed 
here have been highlighted as strong candidates for targeted anticancer therapies, however 
mechanistic insight into how they are regulated may allow for better implementation of these 
strategies for more efficacious treatment. Based on our overall findings here, future studies could 
68 
focus on understanding the genesis of microcalcifications, as inhibiting their formation could lay 
the foundation for the creation of novel therapeutic options.  
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CHAPTER 4: HYDROXYAPATITE NANOPARTICLE-CONTAINING SCAFFOLDS FOR 
THE STUDY OF BREAST CANCER BONE METASTASIS 
PUBLISHED IN BIOMATERIALS (108) 
4.1 Contributors 
Synthetic HA was made by Dr. Debra Lin, and she also performed all material 
characterization (FTIR spectroscopy, XRD, TEM, SEM). I performed all biological assays and 
other experiments. The overall study design was a collaborative effort between Dr. Debra Lin, 
Dr. Lara Estroff, Dr. Claudia Fischbach, and myself.  
4.2 Introduction 
The bone microenvironment is defined by a composite matrix that consists primarily of 
organic collagen and inorganic mineral. Bone mineral is closely related structurally to geologic 
hydroxyapatite (HA) (Ca10(PO4)6(OH)2); however, bone apatites are less crystalline, more 
soluble, and vary in their molecular composition as carbonate ions often substitute for the 
hydroxide and phosphate ions (Ca
10-2x/3
(PO
4
)
6-x 
(CO
3
)
x 
(OH)
2-x/3
) (146). Furthermore, the size and 
crystallinity of bone apatite crystals change during development, growth, and as a result of bone 
pathologies (26, 147). While HA is largely known for its role in conferring structural and 
mechanical properties to bone, it also functions as a bioactive material that directly regulates the 
behavior of both normal and transformed cells (22, 63). For example, HA has been shown to 
enhance normal bone formation (60) and to alter growth and expression profiles of bone 
metastatic tumors (63, 148). Nevertheless, it remains unclear whether or not apatite crystal 
properties directly modulate the pathogenesis of bone diseases, in general, and bone metastasis, 
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in particular. This lack of understanding is partly due to a paucity of culture systems that recreate 
3-D tumor microenvironmental conditions to study changes in tumor cell behavior as a function 
of varying HA nanoscale properties. Therefore, we sought to utilize synthetically prepared HA 
nanoparticles to determine the impact of particle size and crystallinity on mammary cancer cell 
activity.  
The vast majority of advanced stage breast cancers metastasize to the skeleton, forming 
secondary tumors and interfering with bone remodeling to create predominantly osteolytic 
lesions (1). These lesions can lead to severe bone pain, pathological fracture, hypercalcaemia, 
and an overall poor clinical prognosis (64). Osteolysis due to bone metastasis is linked to tumor-
derived soluble factors, such as interleukin-8 (IL-8) and parathyroid hormone related peptide 
(PTHrP), that de-couple the homeostatic balance between bone formation and bone resorption(1, 
66). In particular, IL-8, a molecular mediator of osteolysis (63, 66) and tumor progression (79, 
115), is dramatically upregulated in breast cancer tissue relative to normal breast tissue in 
patients (61), and in breast cancer cells that preferentially metastasize to bone rather than lungs 
(18).  
Though the exact mechanisms by which breast cancer cells preferentially target bone and 
induce pathological remodeling remain unclear, mounting evidence implicates the bone 
microenvironment and specifically HA in this pathogenesis. For example, mammary tumor cells 
increase expression of osteoclastogenic factors upon colonizing bone in vivo (18). Additionally, 
IL-8 secretion by breast cancer cells is enhanced through cell-HA interactions, and stimulates 
osteoclast-mediated osteolysis (63, 66). These studies illustrate the important role that bone 
mineral might play in influencing osteolytic metastasis. Since the size and crystallinity of 
biogenic apatite nanocrystals change as a function of age and disease (26, 147), further study is 
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required to evaluate the role of these nanoscale properties of HA itself on metastatic bone 
disease.  
Tissue engineered (TE) systems, originally created for regenerative medicine, can be 
used as tools to recreate tumor microenvironmental conditions in vitro. Tumor cells seeded in 
scaffold-based TE systems assemble into tumor-like tissues (79) and exhibit phenotypes that 
more closely mimic in vivo behavior as compared to conventional two-dimensional (2-D) 
cultures (148). Furthermore, biologically active materials or molecules, such as mineral particles 
or proteins, can be incorporated into TE scaffolds and presented to cells in a spatially controlled 
manner (137). Bone-like TE systems, including silk-based scaffold systems (100), decellularized 
osteoblast matrices (148), and polymer-HA composites (60, 63, 149) have been created to mimic 
certain features of bone, and several of these systems have been used to study tumor cell 
behavior (63, 148). Since bone metastasis can modify the crystallinity and particle size of the 
mineral component of bone (26), a controllable platform is needed to independently interrogate 
cellular responses to a wide range of HA particle sizes and crystallinities in a pathologically-
relevant culture microenvironment. 
4.3 Materials and Method 
4.3.1 Particle Preparation 
HA nanoparticles were synthesized through a two-step process in which a typical 
precipitation reaction of a calcium salt with a phosphate salt was followed by hydrothermal aging 
of the precipitate to obtain particles with a narrow size distribution (Fig. 4.1). All chemicals for 
these reactions were obtained from Sigma Aldrich and used as received. A solution of 
(NH4)2HPO4 (90 mL, 10 mM) was added drop-wise into a solution of Ca(NO3)2 (150 mL, 10 
mM) under rapid stirring at 4 °C in an ice-water bath for a final calcium to phosphate ratio of 
72 
1.67 (A1-A3 particles). The pH of the starting solutions was adjusted to 9-9.5 with 0.1 M 
NH4OH. Alternatively, in lieu of hydrothermal aging, dry annealing was performed on 
precipitated particles for 3 or 5 days at 200°C (A1-3 and A1-5, respectively). In a second 
reaction, particles were synthesized from a different set of precursors. A solution of Na2HPO4 
(90 mL, 10 mM) was added drop-wise into a solution of CaCl2 (150 mL, 10 mM) under rapid 
stirring at 4 °C until the calcium to phosphate ratio was 1.67 (B1 particles). The pH of the 
starting solutions was adjusted to 9-9.5 with 0.1 M NaOH. In both cases, the reactions were 
allowed to proceed for 1 hr, and then stirred at 20 °C for an additional 12 hrs. The resulting 
opaque suspensions were concentrated 3-fold by centrifugation (Thermo Scientific Sorvall 
Legend RT+ Centrifuge, 3600 g, 5 min) of 45 mL aliquots. After centrifugation, two-thirds of 
the clear supernatant was decanted. The remaining suspension (15 mL) was sonicated for 30 
mins (Bransonic 1510R-MT), placed into a pressure vessel (Parr Instrument Company 276AC-
7304), and aged at 180 °C for the indicated time periods (Table 1) in an oven (model no. 
OV12A, GS Blue M Electric). After aging, the particles were removed from the pressure vessel, 
washed with NH4OH (0.1 M) and deionized water (DI-H2O) to remove soluble salts, rinsed with 
acetone, and then dried at 20 °C (A2, A3, and B1 particles). Poorly crystalline particles were 
collected following the precipitation reaction of Ca(NO3)2 and (NH4)2HPO4. The precipitate was 
washed with NH4OH and DI-H2O, rinsed with acetone, and dried at 20 °C (A1 particles). 
Commercial HA nanopowder obtained from Sigma Aldrich (provider specified particle size 
<200 nm) was used for comparison. 
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Figure 4.1: HA nanoparticle synthesis 
Schematic showing the two-step precipitation reaction to obtain poorly crystalline HA followed by 
hydrothermal aging of the precipitate to obtain crystalline HA nanoparticles 
 
Table 4.1 Summary of particle characterization 
Details of precursor material, hydrothermal aging time, size of particles determined via TEM and XRD, 
and splitting factor determined via FTIR 
4.3.2 Particle Characterization 
Particles were characterized by Transmission Electron Microscopy for shape and 
morphology, and X-ray Diffraction (XRD) and Fourier Transform Infrared (FTIR) Spectroscopy 
for crystallinity and phase information. For TEM, particles were suspended in acetone and 
dropped onto a carbon-coated grid (Electron Microscopy Sciences). Samples were examined by 
brightfield TEM (FEI Tecnai T-12 Spirit, 120 kV), and particle sizes were determined by image 
analysis of the TEM images through ImageJ (NIH). Dried particles were examined via powder 
Sample 
ID
Precipitation 
Precursors
Aging time [hrs]
Length 
[nm]a
(TEM)
Bulk Length 
[nm]b (pXRD) 
Splitting Factor 
(FTIR)c
SIG Commercial Sigma N/A 20-600 125 2.07
A1 Ca(NO3)2, (NH4)2HPO4 0 --- 24 2.56
A2 Ca(NO3)2, (NH4)2HPO4 0.5 20-40 32 3.61
A3 Ca(NO3)2, (NH4)2HPO4 72 60-130 103 3.99
B1 CaCl2, Na2HPO4 1.5 50-120 99 6.60
aThe range of particle lengths observed from TEM micrographs along the {002} axis.
bBulk size of the particles were obtained via Scherrer’s analysis of the {002} peak from pXRD.  
cSplitting factor was obtained from normalizing the sum of the absorbance at 562 cm -1 and 602 cm-1from 
PO4 bond bending (ν4) to the minima between the two peaks to compare relative crystallinities from 
FTIR.
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XRD (PAD-X theta-theta X-ray Diffractometer, Scintag Inc., CuKα 1.54 Å, accelerating voltage 
45 kV, current 40 mA, continuous scan, 2.0 deg/min). Particle sizes were determined from the 
peak broadening of the {002}peak of HA (25.88°) by application of the Scherrer equation  using 
a Al2O3 standard (Software: JADE 9, Materials Data, Inc.). For FTIR (2020 Galaxy Series FT-
IR, Mattson Instruments), KBr pellets were prepared from dried particles and spectra acquired 
(res 4.0 cm
-1
, 253 scans). Particle crystallinities were determined from the splitting factor 
obtained via normalizing the sum of the absorbance at 562 cm
-1
 and 600 cm
-1
 to the minimum 
between the doublet following Weiner and Bar-Yosef (150). 
4.3.3 Scaffold Fabrication 
Porous mineral-containing scaffolds were fabricated by a gas-foaming/particulate 
leaching technique as previously described (60, 63). Briefly, 4 mg of poly(lactide-co-glycolide) 
(PLG) particles (Lakeshore Biomaterials, ground and sieved, average diameter 250 µm), 4 mg of 
PLG microspheres (formed through a double emulsion process, average diameter 5-50 µm), 8 
mg of HA nanoparticles (A1-A3, B1, SIG), and 152 mg of NaCl (J.T. Baker, sieved to a 
diameter of 250-400 µm) were mixed and subsequently cold pressed in a Carver Press (Fred S. 
Carver). The resulting matrices (8.5 mm diameter, 1 mm in thickness) were exposed to high-
pressure carbon dioxide gas (800 psi) inside a non-stirred pressure vessel (Parr Instruments 
4677). Following rapid release of pressure that allowed polymer foaming, scaffolds were soaked 
in de-ionized water for 24 hrs to leach out porogenic NaCl particles. Non-mineral-containing 
(NM) scaffolds that did not contain HA were also fabricated as controls. Prior to cell culture, 
scaffolds were sterilized in 70% ethanol for 30 min and washed five times in sterile PBS. 
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4.3.4 Microscopic Characterization of Scaffolds 
Scaffolds were characterized through TEM, scanning electron microscopy (SEM) and 
brightfield light microscopy to assess particle distribution throughout the polymer matrix. For 
TEM (FEI Tecnai T-12 Spirit, 120 kV), scaffolds were embedded in a UV-active Quetal resin 
(EM Sciences, Fort Washington, PA) and sectioned with a microtome (MT2-B Ultra-Microtome, 
Sorvall Porter-Blum) prior to analysis. For SEM, scaffolds were fractured to expose inner pore 
surfaces and mounted on aluminum SEM stubs (Electron Microscopy Sciences) with carbon tape 
in a manner that allowed subsequent imaging of the exposed surfaces. Particle distribution on 
PLG surfaces were examined on exposed pore surfaces within the scaffold that were unaffected 
by the sample preparation (i.e., not on the fractured surface) and imaged uncoated using a Field-
Emission SEM (Zeiss LEO 1550, 1 kV). Brightfield microscopy of scaffolds was performed on 
an Axio Observer.Z1 (Zeiss).  
4.3.5 Analysis of Protein Adsorption on Scaffolds 
To quantify the degree of protein adsorption as a function of HA nanoparticle 
characteristics, scaffolds were incubated in complete DMEM (cDMEM ; i.e., DMEM 
[Invitrogen] supplemented with 10% fetal bovine serum [Tissue Culture Biologicals] and 1% 
penicillin/streptomycin [Invitrogen]). Following 30 min of incubation, scaffolds were washed 
twice in PBS (Invitrogen) and then sonicated (Branson Sonifier 150) in RIPA buffer (Sigma). 
After centrifugation, total protein in the supernatant was quantified using a Bicinchonic Acid 
(BCA) Kit (Thermo) and colorimetric analysis on a plate reader (Tecan M1000) according to 
manufacturer’s instructions. Additionally, scaffolds were incubated in DMEM supplemented 
with 20 µg/mL of fibronectin (Sigma) and adsorbed fibronectin was analyzed by 
immunofluorescence. Briefly, scaffolds were fixed with 10% formalin, rinsed twice in PBS, and 
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then incubated with a polyclonal rabbit anti–fibronectin antibody (Sigma). After a second wash 
with PBS containing bovine serum albumin, scaffolds were incubated with an Alexa Fluor 488 
secondary antibody (Molecular Probes). Whole-mount scaffolds were imaged using an epi-
fluorescence microscope (Zeiss Axio Observer.Z1).  
4.3.6 Cell Culture 
Human MDA-MB231 breast cancer cells (ATCC) were maintained under standard 
culture conditions (37°C, 5% CO2) in cDMEM. For 3-D cell culture, scaffolds were statically 
seeded with 1.5 million MDA-MB231 cells and subsequently maintained under dynamic culture 
conditions on an orbital shaker for up to 10 days as previously described (63). 
4.3.7 Analysis of Ion Content in Media from Scaffolds 
To determine changes in calcium and phosphate content in media during culture, 
acellular NM- and A1-scaffolds were incubated in cDMEM under standard culture conditions 
(37°C, 5% CO2). The media was harvested after 2 days, digested in 5% nitric acid, and analyzed 
with inductively coupled plasma spectroscopy (ICP; ICAP 61E Trace Analyzer, Thermo). 
Additionally, ICP analysis was performed with media harvested from tumor cell-seeded NM- 
and A1-scaffolds after 2 days of 3-D culture. 
4.3.8 Characterization of Tumor Cell Behavior 
To measure tumor cell growth, tumor constructs were harvested 30 min after seeding 
(day 0) and again after 72 hrs. Constructs were washed five times in PBS and mechanically 
disintegrated, before being sonicated (Branson Sonifier 150) in lysis buffer (25 mM Tris-HCl, 
0.4 M NaCl, 0.5% SDS). Subsequently, lysates were centrifuged, and the supernatant was 
assayed for DNA content using PicoGreen® assay (Invitrogen) and a fluorescence plate reader 
77 
(Tecan M1000) according to manufacturer’s instructions. Protein secretions in media from 
constructs were also analyzed 72 hrs after seeding. Briefly, breast cancer cell-seeded scaffolds 
were transferred to fresh well plates 24 hrs prior to harvesting media for analysis, and culture 
medium was changed to DMEM containing 1% FBS. IL-8 of harvested media was measured via 
ELISA (R&D) according to manufacturer’s instructions and normalized to DNA content to 
account for differences in cell number. For analysis of IL-8 expression, RNA was collected by 
dissolving tumor cell-seeded scaffolds in TRIzol® (Invitrogen) and then extracting total RNA 
according to manufacturer protocol. Total RNA (1 μg) was then reverse transcribed to cDNA 
(High Capacity cDNA Reverse Transcription Kit with random hexamers [(Applied 
Biosystems)]), and subjected to real-time RT-PCR (25 ng template, run in triplicate) using 
SYBR green detection (Quanta) on an Applied Biosystems 7500 System. Primer sequences for 
human IL-8 (fwd: 5’-agaaaccaccggaaggaaccatct-3’, rev: 5’-agagctgcagaaatcaggaaggct-3’) and β-
actin (fwd: 5’-aatgtggccgaggactttgattgc-3’, rev: 5’-aggatggcaagggacttcctgtaa-3’) were 
synthesized by IDT Technologies. β-actin was used as an endogenous loading control gene, and 
relative quantification was performed using the ΔΔCt method as previously described (126). 
4.3.9 Statistical Analysis 
One-way ANOVA and Student’s t-test were used to determine statistical significance 
between conditions. Tukey’s post test was used for pairwise comparisons. Significance between 
groups and NM, A2, and B1 scaffolds (see Table 1) are denoted by (*), (#), and (o) respectively. 
In all cases, P<0.01 is indicated by a single symbol and P<0.005 is denoted by double symbols. 
For all experiments, sample conditions were run in triplicate or greater. Data are presented as 
averages, and error bars represent standard deviations.  
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4.4 Results 
4.4.1 Particle Synthesis and Characterization 
Synthetic HA (sHA) with varying nanoscale characteristics can be formed via solution-
based precipitation reactions, hydrothermal synthesis, electrodeposition, or sintering (146, 151). 
The sHA nanoparticles used for the fabrication of mineral-containing scaffolds were obtained 
from either a two-step synthesis involving a precipitation reaction followed by hydrothermal 
aging or a commercial source for comparison (Fig. 4.1, Table 4.1). To synthesize poorly 
crystalline particles (A1), solutions of calcium and phosphate salts were mixed together rapidly 
at low temperature. Remaining particles (A2, A3, and B1) were prepared by hydrothermally 
aging a suspension of the particles from the precipitation reaction. The size and crystallinity of 
the particles increased with aging time (A2, A3), and could also be varied by changing the 
precursor salts (B1).  
Particle shape and size distributions of both the sHA and commercial HA were 
determined by TEM (Fig. 4.2). The sHA particles that were formed from the initial precipitation 
reaction (A1) were small and poorly crystalline; however, hydrothermally aging these same 
particles resulted in the formation of uniform, larger, faceted, and elongated particles with a 
narrow size distribution (A2 and A3). Similar to previous observations (146), the length of the 
rod-like particles increased with aging time from 20-40 nm after 0.5 hrs of aging (A2) to 60-170 
nm after 72 hrs of aging (A3). Using a different set of precursor salts and shorter aging time (1.5 
hrs), rod-like particles (B1), with lengths similar to A3 (50-150 nm), were also obtained. In 
contrast to the sHA particles, the SIG particles were spherical and exhibited a wide range of sizes 
(20-600 nm in diameter). 
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Figure 4.2: TEM images of HA particles used to prepare mineral-containing PLG-scaffolds 
(A) and (B) Commercial Sigma Aldrich particles, (shown at low [SIGa], and high [SIGb] magnification), 
(C-F) HA particles synthesized from Ca(NO3)2 and (NH4)2HPO4 precursors with hydrothermal aging 
times of 0 hrs (A1), 0.5 hrs (A2), and 72 hrs (A3), and particles synthesized from CaCl2 and Na2HPO4 
precursors aged for 1.5 hrs (B1). 
 
Figure 4.3: XRD and FTIR for sHA 
(Left) pXRD patterns of particles SIG, A1-A3, and B1. All samples are confirmed to be HA. Major peaks 
have been labeled with HA crystal indices. (ICDD PDF no. 09-0432) (152) FTIR spectra of particles SIG, 
A1-A3, and B1. Positions of characteristic HA peaks are indicated. 
2 22 42
In
te
n
s
it
y
 [a
.u
.]
2-theta [deg]
* * **
{0
0
2
}
{2
0
2
}
{2
11
}
{3
00
}
50070090011001300
A
b
s
o
rb
a
n
c
e
 [a
.u
.]
Wavenumber [cm-1]
63
 0
56
260
2
96
11
0
3
 5
1
0
5
0
1
1
0
5
A1
A2
A3
B1
SIG
SIG
A1
A2
A3
B1
80 
All of the synthetic particles were pure HA according to powder X-ray diffraction (pXRD) (Fig. 
4.3, left). The diffraction pattern of the SIG particles, however, contained unidentified peaks in 
addition to those indexed to HA (ICDD PDF no. 09-0432). The pXRD also provides information 
regarding the particle size and crystallinity. Scherrer analysis of the {002} peak width (25.88°) 
revealed that the average length of the particles to be 24 nm (A1), 32 nm (A2), 103 nm (A3), 100 
nm (B1), and 125 (Table 4.1). The increase in the number of clearly resolvable peaks at higher 
angles for A3 and B1 particles suggest an increase in crystallinity compared to A1 and A2 
particles. 
FTIR results confirmed the increase in crystallinity for the larger particles obtained from 
longer hydrothermal aging times and varying precursor salts (A3, B1). The absorbance at 630 
cm
-1 
is attributed to structural hydroxides in HA and is known to increase with enhanced 
crystallinity (Fig. 4.3, right) (153). This absorbance was undetectable for the poorly crystalline 
HA (A1), and increased in intensity for nanoparticles A2, A3, and B1. The increase in 
crystallinity was further confirmed from calculation of the splitting factor (Table 4.1). The 
splitting factor, which quantifies the degree of splitting of the PO4 bond bending (ν4) peaks (562 
cm
-1
 and 600 cm
-1
), is known to increase with increasing crystallinity (150). Interestingly, 
although A3 and B1 are similar in length, B1 had nearly twice as large a splitting factor, 
indicating differences in crystallinity between the two similarly sized particles made from 
different precursor salts (Table 4.1).  
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Figure 4.4: Visualization of pore structure and HA distribution in scaffolds 
Brightfield micrographs show no change in architectural properties with addition of hydrothermally aged 
particles (A, B). SEM micrographs of A3-scaffold (C, E) and SIG-scaffold (D,F) show the distribution of 
A3 and SIG particles on pore surfaces exposed after fracture of a scaffold.  Regions of high particle 
density (*), low particle density (O), and pores in the scaffold (#) were observed for both scaffolds (C,D).  
Residual salt crystals are indicated (x).  Arrows point to individual A3 particles (E) and SIG particles (F). 
4.4.2 Scaffold Characterization 
The micro- and nano-architecture of the scaffolds was analyzed via brightfield light 
microscopy, SEM and TEM. Mineral-free (NM-scaffolds), SIG-scaffolds, and A3-scaffolds were 
C D
E F
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compared to assess the integration of different particles into the bulk-PLG. Incorporation of the 
SIG and A3 nanoparticles did not change the microarchitectural characteristics (i.e., pore size 
and wall thickness) of the scaffolds compared to the NM-scaffold as shown by brightfield light 
microscopy (Fig. 4.4A-B). The distribution of both A3 and SIG particles on pore surfaces within 
the scaffolds was revealed by SEM micrographs.  Despite the differences in particle morphology, 
similar surface coverage was observed for both the rod-like A3 particles and spherical SIG 
particles.  Both scaffold types contained regions of high and low particle density, as well as areas 
without surface-associated HA (Fig. 4.4C-F). High magnification SEM images of the A3 and 
SIG scaffolds (Fig. 4.4E-F) further illustrated that the surface topography is dictated by the 
morphology of the incorporated particles and reflects the rod-like and spherical morphology of 
A3 and SIG particles. TEM micrographs of sectioned A3-scaffolds revealed that HA particles 
were localized at or near the pore surfaces, with a small number of particles completely 
embedded within the bulk-PLG (Fig. 4.5). This distribution of particles suggests that a majority 
of the particles are accessible for interaction with seeded cancer cells. 
 
Figure 4.5: TEM micrograph of sHA scaffold 
The distirbution of the particles (indicated by arrows) in the bulk (indicated by ‘O’) and the pores 
(indicated by ‘#’) of the polymeric matrix is shown.  Inset: Higher magnification image of the area 
indicated by a box. 
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4.4.3 Serum Protein Adsorption 
To assess whether the HA nanoscale characteristics modulate cellular interactions with 
scaffolds, we next determined the capacity for protein adsorption of the different mineral-
containing scaffolds. When incubated in serum-containing media (DMEM + 10% FBS), mineral-
containing scaffolds adsorbed significantly more protein than control NM-scaffolds, and 
furthermore, the scaffolds with the smallest and least crystalline HA nanoparticles (A1) adsorbed 
the most serum proteins, as determined by a colorimetric assay (Fig. 4.6A). Specifically, 
scaffolds with poorly crystalline particles (A1) adsorbed two-fold more serum protein as 
scaffolds with 103 nm long particles (A3). Furthermore, A3-scaffolds adsorbed significantly 
more protein than the more crystalline B1 scaffolds, yet these two particles did not vary in size. 
Incubating scaffolds in pure solutions of fibronectin, an adhesive serum protein that readily 
adsorbs onto most biomaterial surfaces (154), yielded similar trends as indicated by fibronectin 
immunofluorescence (Fig. 4.6B). To control for changes in surface area as a function of particle 
size and/or shape, fibronectin adsorption experiments were repeated with scaffolds containing 
HA nanoparticles in amounts normalized to surface area. Under these conditions, scaffolds 
containing smaller, poorly crystalline nanoparticles (i.e. 20 nm long) adsorbed significantly more 
fibronectin relative to those with longer, more crystalline particles (i.e. 80 nm and 100 nm long) 
(Fig. 4.6C).  These results suggest that HA particle characteristics, in addition to purely surface 
area, regulate the adsorption of serum proteins that may in turn modulate cell behavior.  
84 
 
Figure 4.6 Protein adsorption for sHA scaffolds (A) Serum protein adsorption on non-mineral-
containing (NM) and mineral-containing (A1-A3, B1, SIG) scaffolds as quantified via colorimetric BCA 
analysis of scaffold lysates prepared after incubation with serum-containing cell culture media. (B) 
Immunofluorescence analysis of fibronectin (FN) adsorption onto non-mineral-containing (NM) and 
mineral-containing scaffolds containing small, poorly crystalline (A1) and highly crystalline HA particles 
(B1). Significance between groups and NM, A2, and B1 scaffolds are denoted by (*), (#), and (o) 
respectively. (C) FN adsorption as quantified by BCA analysis indicated that smaller crystals in scaffolds 
stills adsorbed more protein, even when mass of crystals used was less to normalize surface area within 
scaffold.   In all cases, P<0.01 is indicated by a single symbol and P<0.005 is denoted by double symbols. 
 
C
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4.4.4 Scaffold and Particle Integrity in Culture Conditions 
To determine if HA nanoparticle solubility contributes to calcium and phosphate content 
in media, which during cell culture could lead to differences in cell behavior, the elemental 
composition of media harvested from scaffolds was analyzed via ICP (Fig. 4.7). A1-scaffolds 
were used for this experiment since poorly crystalline HA has increased solubility compared to 
more crystalline HA (146) and would be most susceptible to potential dissolution. Analysis was 
performed on both cell-seeded and cell-free scaffolds, revealing that the calcium concentrations 
remained unchanged for all conditions and matched concentrations found in cDMEM. Similarly, 
non-seeded scaffolds exhibited unfettered phosphorous levels equal to concentrations found in 
cDMEM. In contrast, phosphorus concentrations increased for both the NM and A1-scaffolds 
that were seeded with cells. This increase was attributed to the presence of the cancer cells rather 
than the dissolution of HA particles. Overall, our findings show that any observed effects of 
mineral-containing scaffolds on cell behavior are related to cell-material interactions with HA 
nanoparticles and not the presence of increased levels of soluble calcium and phosphorous. 
 
Figure 4.7: Solubility of sHA in scaffolds Calcium (155) and phosphorus (black) content of media 
harvested from non-mineral-containing (NM) and mineral-containing (A1) scaffolds after 2 days of 
culture in the presence and absence of MDA-MB231 breast cancer cells as determined by ICP. Culture 
media incubated for the same period of time, but not exposed to scaffolds or cells was used as a control 
(Media). 
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4.4.5 Effect of HA Crystallinity and Particle Size on MDA-MB231 Adhesion and Growth 
To determine the relevance of mineral characteristics to breast cancer cell colonization 
and growth within bone, we seeded MDA-MB231 breast cancer cells into mineral-containing 
PLG scaffolds and evaluated their adhesion and proliferation as a function of HA nanoparticle 
characteristics. In comparison to NM scaffolds, all of the mineral-containing scaffolds enabled 
significantly more cell adhesion as detected by DNA quantification following initial cell seeding 
(Fig. 4.8A). Similar to the increased protein adsorption (Fig. 4.6), cell adhesion was greatest 
within scaffolds containing small, poorly-crystalline nanoparticles (A1) as compared to larger 
and more crystalline HA scaffolds (A2, A3, and B1) suggesting a possible link between HA-
regulated protein adsorption and cell adhesion. Likewise, significantly more cells adhered to A3 
scaffolds than B1 scaffolds, suggesting that increased HA crystallinity inhibits breast cancer cell 
adhesion by suppressing protein adsorption. Importantly, tumor cell proliferation was also 
affected by the presence of different HA nanoparticles and followed similar trends as observed 
for cell adhesion (Fig. 4.8B).  
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Figure 4.8: Effect of sHA particle characteristics of growth and adhesion of MDA-MB231 cells (A) 
MDA-MB231 cell adhesion onto non-mineral-containing (NM) and mineral-containing scaffolds (A1-A3, 
B1, SIG) as quantified via PicoGreen DNA assay of cell lysates 3 hours after seeding. (B) MDA-MB231 
growth 3 days after seeding of non-mineral-containing (NM) and mineral-containing scaffolds (A1-A3, 
B1, SIG) as analyzed by PicoGreen DNA assay. Values are depicted relative to day 0 to account for 
variations in initial cell adhesion between the individual groups. Significance between groups and NM, 
A2, and B1 scaffolds are denoted by (*), (#), and (o) respectively. In all cases, P<0.01 is indicated by a 
single symbol and P<0.005 is denoted by double symbols. 
 
Figure 4.9 Effect of sHA particle characteristics on IL-8 production by MDA-MB231 cells (A) IL-8 
secretion by MDA-MB231 breast cancer cells as analyzed through ELISA of conditioned media collected 
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from non-mineral-containing (NM) and mineral-containing scaffold cultures (A1-A3, B1, SIG). Values 
were normalized to cell numbers as determined via PicoGreen DNA assay to account for changes in cell 
proliferation. (B) IL-8 mRNA expression by MDA-MB231 breast cancer cells as analyzed through 
quantitative real-time RT-PCR of lysates collected from non-mineral-containing (NM) and representative 
mineral-containing scaffold cultures (A1, B1, SIG). Values are shown as normalized to expression levels 
in NM scaffold cultures. Significance between groups and NM, A2, and B1 scaffolds are denoted by (*), 
(#), and (o) respectively. In all cases, P<0.01 is indicated by a single symbol and P<0.005 is denoted by 
double symbols. 
4.4.6 IL-8 Secretion by MDA-MB231 Cells as a Function of HA Crystallinity and Particle 
Size  
To evaluate the effect of HA nanoparticle characteristics on the osteolytic capability of 
breast cancer cells, we analyzed IL-8 secretion by MDA-MB231 cells in the different scaffolds. 
Interestingly, in contrast to cell adhesion and proliferation, IL-8 secretion was inversely 
regulated by HA crystallinity and size. Specifically, cellular secretion of IL-8 was greatest in 
scaffolds that incorporated highly crystalline HA (B1) (Fig. 4.9A), while scaffolds that contained 
similarly sized, but less crystalline HA (A3) secreted significantly less IL-8. Furthermore, tumor 
cells cultured in scaffolds with the smaller and less crystalline particles (A1, A2) secreted less 
IL-8 relative to the highly crystalline particles (B1). These changes in secretion were mimicked 
at the expression level, as real-time RT-PCR demonstrated upregulation of IL-8 in cells seeded 
in scaffolds containing larger HA crystals as compared to less crystalline HA conditions or NM 
controls (Fig. 4.9B). To confirm that these outcomes resulted from nanoparticle characteristics 
and not a change in surface area due to particle size and/or shape, experiments were repeated 
with scaffolds containing HA nanoparticles in amounts normalized to surface area. In these 
experiments, the scaffolds containing larger, more crystalline HA still increased IL-8 secretion 
(Fig. 4.10A). Culture with dry annealed particles, which presumably differ only in crystallinity 
but not size, indicated similar trends in IL-8 levels, though sample size was insufficient to 
establish statistical significance in this measure due to variability in DNA quantification (Fig. 
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4.10B). Taken together, these data suggest a role of HA nanoparticle characteristics, beyond size, 
in regulating the osteolytic potential of MDA-MB231 breast cancer cells. 
 
Figure 4.10: IL-8 secretion in response to varying geometry and crystallinity of sHA particles in 
scaffolds (A) IL-8 secretion by MDA-MB231 breast cancer cells as analyzed through ELISA of media 
collected from mineral-containing scaffold cultures with mass of HA per scaffold normalized by surface 
area available within scaffold. Values were normalized to cell numbers as determined via PicoGreen 
DNA assay to account for changes in cell proliferation. (B) Total IL-8 and DNA in scaffolds containing 
dry-annealed HA crystals. In all cases, P<0.01 is indicated by a single symbol and P<0.005 is denoted by 
double symbols. 
4.5 Discussion 
Since bone metastasis often leads to the formation of osteolytic lesions [8] that are 
characterized by less crystalline and smaller apatite particles relative to healthy bone [2], studies 
of breast cancer bone metastasis would benefit from HA-containing scaffold systems in which 
particle size and crystallinity can be independently varied. While 3-D culture approaches have 
enhanced the physiological relevance of in vitro studies (79, 120), models to investigate cell-
mineral interactions in response to specific HA nanoparticle characteristics currently do not 
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exist. Commercially available HA particles, which are routinely employed for the fabrication of 
mineral-containing scaffolds (60, 63), are heterogeneous in size, shape, and chemical 
composition as shown by us (Fig. 4.2A, B) and others (156). Gas-foamed/particulate-leached 
polymer composite scaffolds have previously been used to effectively present mineral to cultured 
cells (60, 63), and we have applied this platform to present hydrothermally grown HA particles 
with tunable nanoscale characteristics to cells in a 3-D culture context. Specifically, we have 
used these scaffolds to study the effects of HA particle size and crystallinity on breast cancer cell 
behavior and have demonstrated that altering the crystal properties of HA may control the 
osteolytic and metastatic phenotype of breast cancer cells. 
Several methods have previously been used to synthesize HA nanoparticles with narrow 
size distributions (151, 157). Many of these methods depend on the presence of surfactants or 
fractionation to control the size distribution, and the resulting particles have organic impurities 
and are produced in low yields (158, 159). Here, we describe an optimized technique for the 
synthesis of HA nanoparticles, which does not require additives or elaborate separation 
techniques to obtain narrow size distributions. The two-step process involves a wet chemical 
precipitation followed by hydrothermal aging and yields hydroxyapatite nanoparticles of tunable 
sizes, crystallinity, and, possibly, composition. Compared to conventional hydrothermal HA 
particle synthesis methods whereby particles are made directly in hydrothermal reactions (146, 
151), the division of the process into two steps ensures size uniformity by separating the 
nucleation and growth processes of the HA particles. The precipitation step nucleates HA seed 
crystals, while the hydrothermal aging step controls the growth of the seed crystals into larger 
particles (160). To generate HA nanoparticles of systematically varying crystallinity and size, we 
varied the hydrothermal aging times (A1, A2, A3) and utilized different precursor salts (B1), 
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while maintaining temperature and pH. Extensive characterization via TEM, SEM, FTIR, and 
pXRD defined the specific nanoscale properties of the resulting particles (Table 4.1). In 
particular, the importance of the choice of precursor salts is evident in comparing A3 particles 
and B1 particles, which exhibited similar length, but varied in crystallinity. The resulting 
particles ranged from having biologically relevant lengths and crystallinities (A1) (26, 147) to 
longer dimensions and higher crystallinities (A2, A3, B1), enabling us to systematically evaluate 
the effects of nanoparticle size on tumor cell behavior. Incorporation of these well-defined 
particles into PLG scaffolds resulted in the presentation of the particles at the porous surface of 
the scaffolds, enabling interactions with seeded cells (Fig. 4.5). Such scaffold systems will be 
critical for the identification of parameters for the design of non-tumorigenic mineral-containing 
and mineral-containing matrices for bone regeneration.  
It has been shown that HA and other calcium phosphate surfaces efficiently adsorb 
adhesive and serum proteins (e.g. fibronectin) that are crucial in mediating cell attachment and 
tissue formation (63, 84, 161, 162). Other studies with different material systems have 
demonstrated that nanoparticle size modulates protein adsorption (163), and our results further 
indicate that altering the nanoscale properties of HA affects overall protein adsorption behavior 
(Fig. 4.6). Specifically, our studies reveal that the overall magnitude of protein adsorption 
decreases monotonically with increasing HA crystal size. Additionally, decreasing the 
crystallinity of HA nanoparticles (assessed by the IR splitting factor) independent of overall size 
also increases the protein adsorption capacity of the scaffolds, as indicated by differences in 
serum protein adsorption between scaffolds fabricated from particle sets A3 and B1 (Fig. 4.6A). 
Overall available scaffold surface area may vary based on particle size and shape, and these 
changes may contribute to the observed differences in protein adsorption. Nevertheless, our 
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results measured with scaffolds in which the amount of HA was normalized to surface area 
indicate that nanoparticle characteristics also modulate total adsorption capacity (Fig. 4.6C). 
These changes in protein adsorption may have important implications for general bone function 
as well as metastatic bone disease, as altered protein adsorption broadly modulates cell adhesion, 
proliferation, and survival of osteoclasts (164), osteoblasts (22, 161, 162), and breast cancer cells 
(63). It is likely that adsorbed RGD-containing proteins, such as fibronectin, may be involved in 
these effects, as these biomolecules regulate cell attachment (165), focal adhesion formation 
(166), and proliferative signaling pathways (167). 
Cell behavior is affected by mineral characteristics. For example, osteoblasts respond 
differently to HA as compared to tricalcium phosphate (TCP) (168), and amorphous calcium 
phosphate and highly crystalline HA exhibit varying levels of osteoconductivity (76). Similarly, 
HA and TCP elicit varying levels of differentiation in pre-osteoclasts (169) and resorptive 
activity in mature osteoclasts (170). Additionally, the results of our study indicate that nanoscale 
mineral properties are crucial regulators of tumor cell behavior. In particular, scaffolds that 
contained smaller and less crystalline particles and adsorbed more adhesive proteins out of serum 
also supported more initial breast cancer cell adhesion and proliferation (Fig. 4.7A, B). While 
enhanced secondary tumor formation in the bone is generally attributed to resorptive release of 
growth factors and other soluble cues (1), our data support the idea that direct interactions with 
the mineral matrix could give rise to increased tumor formation and cancer cell growth in the 
bone microenvironment. Pathologically, our data suggest that exogenously introduced HA may 
regulate cellular adhesion and growth through adhesive protein adsorption, and thereby serve as 
a high affinity-substrate for metastasizing breast cancer cells. In vivo, TE bone has been observed 
to serve as a metastasis target (100), and recent evidence indicates that cancer cell-bone matrix 
93 
interactions activate invasive and proliferative potential (148), further supporting the contention 
that HA may be involved in the breast cancer cell avidity for bone. 
 IL-8 secretion is linked closely to osteoclast-mediated osteolysis in metastatic breast 
cancer (66) and is known to be enhanced through cell-HA interactions (63). Our current study 
suggests that the nanoscale properties of HA strongly affect overall IL-8 expression, with larger 
and more crystalline HA stimulating significant IL-8 upregulation in breast cancer cells (Fig. 
4.8). This finding is somewhat surprising since IL-8 expression may be expected to correlate 
with protein adsorption, as integrin engagement affects IL-8 transcription in certain cancers (44). 
However, upon adsorption onto surfaces, in particular crystals, protein conformation, and 
possibly the presentation of cellular binding sites, may change (84, 171). Therefore, it is possible 
that though more protein is adsorbed to the smaller, less crystalline particles, these proteins no 
longer have their native conformation and do not trigger IL-8 expression. It is also possible that 
the cell-mineral interactions affect IL-8 production by breast cancer cells through other 
mechanisms. For example, nanoparticles could become loosened from the scaffold during cell 
growth and induce an inflammatory reaction, as environmental particles are known to activate 
proinflammatory signaling (172). Although not clear from the current study, our mineral-
containing system could be further employed to investigate these possibilities. 
While the insights provided by our system have pathological significance, future studies 
can take into account the broader complexity of breast cancer and the bone microenvironment. 
For example, in this study we have solely tested the cellular response of a highly metastatic 
breast cancer cell line, but it is possible that non-metastatic breast cancer cells may also be 
responsive to HA. In fact, HA may promote growth and invasiveness in non-metastatic breast 
cancer cell lines, and this response may be clinically significant, as microcalcifications in the 
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breast are associated with malignancies and could potentially play a role in driving tumor 
progression (173). Furthermore, this platform could be used to investigate interactions between 
breast cancer cells and osteoblasts and osteoclasts to fully recapture the cellular aspect of bone. 
Both of these cell types induce the osteolytic capability of breast cancer cells (63, 66, 174), and 
both may be affected by nanoscale HA characteristics (175, 176). Mineral-containing tumor 
models incorporating hydrothermally-aged HA nanoparticles provide the capability to address 
these aspects of the bone microenvironment and thereby have the potential to improve our 
understanding of the molecular mechanisms underlying bone metastasis that may ultimately 
enable the discovery of novel therapeutic targets for patient care. Moreover, the use of sHA in 
culture models could broadly provide insight into basic bone biology and the potential risks of 
new classes of mineral-containing and mineral-containing matrices for bone regenerative 
technologies. 
4.6 Conclusions 
We have created a mineral-containing platform that recreates certain aspects of the 3-D 
bone microenvironment by incorporating well-defined sHA nanoparticles into a TE biomaterial 
scaffold. We have used this platform to investigate the effect of nanoscale HA characteristics on 
breast cancer cell behavior, and our study indicates that the nanoscale properties of HA play a 
key role in regulating breast cancer cell behavior. In conjunction with previous evidence that 
osteolytic lesions are sites of low-crystallinity and smaller mineral particles (26), this work 
suggests that altering the nanoscale properties of microenvironmental bone mineral could play a 
role in the formation of a metastatic niche in bone supporting enhanced tumor cell colonization 
and growth. Specifically, we have demonstrated that smaller, less crystalline HA particles 
increase cellular adhesion and growth, while larger and more crystalline HA enhances breast 
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cancer cell expression of the osteolytic factor IL-8. Overall, our findings provide new evidence 
that the vicious cycle of bone metastasis is not only mediated by growth factors in the bone 
microenvironment, but also by the actual materials characteristics of the mineral matrix.  
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CHAPTER 5: MINERAL-CONTAINING FILMS TO STUDY INTEGRIN-MEDIATED 
CELL-HA INTERACTIONS 
5.1 Contributors 
I performed all of the experiments in this chapter independently. However, I was assisted 
greatly by technical insights from Dr. Debra Lin and Dr. Lara Estroff. Dr. Claudia Fischbach and 
I designed this study. 
5.2 Introduction 
Osteopontin (OPN) has been identified as both a marker and mediator of metastatic 
breast cancer. Patient data indicates that ectopic expression of highly-phosporylated OPN in 
breast tissue is a common feature in mammary malignancies (142), and levels of soluble OPN in 
plasma are generally observed to be elevated in cases of bone metastasis (177, 178). Work with 
cancer cell lines has also revealed that OPN is an integral part of the recently developed bone 
metastasis gene signature (18, 110, 179). Functionally, OPN is thought to be a major player in 
cell attachment (127), cell motility and migratory capacity (180), and matrix metalloproteinase 
(MMP)-mediated extravasation (181). Given the importance of all of these cellular 
characteristics in controlling tumor progression and metastasis, further study of the specific 
effect of OPN on mammary tumor cells in justified. 
Notably, OPN was first identified as a protein within bone (182). Further studies have 
indicated its natural presence in other tissues, but OPN remains one of the most abundant 
noncaollagenous proteins in bone (183). The accumulation of OPN in bone may be due to its 
intimate interaction with hydroxyapatite (HA), the inorganic mineral component of bone (30, 
184). The proclivity for OPN to interact with and bind to HA is controlled by its poly-aspartic 
acid domain: this long chain of negatively-charged aspartate residues mediates electrostatic 
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attraction to the mineral substrate (47, 185, 186). In addition to its poly-aspartic acid domain, 
OPN contains cell attachment sequences, including the well known RGD motif (48, 187). In 
bone, OPN is known to mediate adhesion of both osteoblasts and osteoclasts, helping to facilitate 
a wide variety of cellular activities required normal skeletal function. For example, OPN is 
involved in homing and adhesion of osteoblast progenitor cells during de novo mineralization 
(188). OPN has also been discovered to be critical in allowing osteoclast attachment and the 
initiation of bone turnover (189, 190). The ability of OPN to bind mineral and subsequently 
dictate cellular behavior may play an important role in breast cancer metastasis, given that 
mammary tumors are frequently associated with ectopic microcalcifications composed of HA 
that are detected by mammography (24, 27, 130).  
Despite mounting evidence suggesting that HA directly contributes to the genesis of 
malignancies (27), and previous studies that have implicated HA as a potentially pro-metastatic 
biomaterial (23, 24, 63), no definitive mechanisms by which these phenomena could potentially 
occur have been suggested. In particular, HA has been shown to induce secretion of pro-
tumorigneic cytokines, including interleukin-8 (IL-8). Here, we investigate the ability of OPN to 
mediate the pro-metastatic effects of HA. The results could be physiologically relevant 
considering the ability of OPN to mediate cell-mineral interactions and the consistent 
overexpression of OPN in breast cancer. Due to its RGD-domain, OPN can interact with cancer 
cells through integrin receptors (191). Integrins are the most widely-studied mediators of cell-
ECM interactions. They are a large family of heterodimeric surface receptors that as a whole 
bind a wide range of ECM proteins to anchor cells through the formation of focal adhesions. 
Focal adhesions are not purely structural complexes, as they are fully capable of activating 
intracellular signaling machinery (46). In particular, integrin engagement is often accompanied 
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by activation of focal adhesion kinase (FAK), which in turn stimulates a host of proliferative and 
transcriptive cellular responses (192). Understanding how HA affects integrin engagement will 
help to reveal how mineral acts as a microenvironmental regulator of cell behavior through ECM 
binding. Past work has demonstrated that integrin engagement can be affected by various 
features in the tumor microenvironment including three-dimensionality (44) and protein folding 
(21), and it is quite possible that mineral acts in a similar manner.  
Because mammary tumors have a predilection to metastasize to bone and are often found 
in conjunction with microcalcifications in the breast, the relationship between breast cancer cells 
and HA should be explored. Drawing from Paget’s seed and soil theory, it is possible that HA 
microcalcifications represent a microenvironmental feature that primes cancer cells to colonize 
the bone. Though HA interactions with proteins found in ECM have been widely observed, few 
connections to how these effect integrin engagement and cell behavior, especially in the context 
of cancer, have been found. Further studies into the underlying molecular mechanism are 
required to truly exploit this as a point of therapeutic intervention. To help address this 
challenge, we developed a mineral-containing film model that allowed the study of integrin 
function in the presence of HA. This model has been designed to reflect certain features of 
malignant microcalcifications like mineral-clustering that may be critical to recreating effects of 
tissue structure on cell-ECM interactions. Our findings indicate that integrin engagement may 
indeed be a mediator of HA-regulated tumor progression and illustrate the need for mineral-
containing platforms in studies of metastatic breast cancer.  
5.3 Materials and Methods 
5.3.1 Film fabrication and characterization 
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Films were fabricated based on a modified protocol previously used for spin casting poly-
(lactide-co-glycolide) (PLG) (193). A theoretical film thickness of 30 nm was used to define 
parameters based on an equation developed by Daly et al. (194). First, glass slides (Fisher) were 
cut to 25 mm X 25 mm using a diamond scribe. They were then washed sequentially in acetone, 
isopropyl alcohol, and DI water in an ultrasonic bath to clear dust and any organic residue. PLG 
solutions were prepared by dissolving PLG pellets (Lakeshore Biometerials) in chloroform 
(Sigma). PLG concentration was varied between 1% and 2% by weight. For mineral-containing 
films, HA particles (Sigma) were dispersed into the PLG solutions at varying weight 
concentrations. To ensure optimal dispersion, the solutions were subjected to sonication just 
prior to film deposition.  
Film deposition was performed under clean room conditions using a spin casting set up. 
The spin speed was set to 2000 rpm, and casting took place over 60 seconds. 1 mL of PLG 
solution (either mineral-containing or not) was used for each glass square (Fig. 5.1). Just after 
spin casting, the films were placed in an oven at 60°C for 2 hours. This allowed excess 
chloroform to completely evaporate. After casting of films, they were stored for no more than 1 
week in sterile DI-water prior to use in cell culture. Both mineral-containing films and non-
mineral-containing films were generated. 
Films were characterized by AFM and protein adsorption measurements. AFM was 
performed in tapping mode on 100 µm
2
 sampled areas to determine overall mineral distribution 
and surface roughness. For determining overall levels of protein adsorption, films were first 
incubated with 50 ng/mL of recombinant human OPN (R&D systems) for 1 hour to enable 
adsorption. This OPN variant is expected to be highly-phosphorylated according to the 
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manufacturer. After one hour, the OPN-containing solution was collected and unadsorbed 
protein was measured through ELISA (R&D) according to manufacturer’s instructions.  
5.3.2 Scaffold fabrication 
Three-dimensional (3-D) non-mineral-containing and mineral-containing scaffolds were 
created according to a past protocol (60). Scaffolds were also composed of PLG and HA 
nanoparticles (Sigma), and were synthesized through a gas-foaming/particulate-leaching 
procedure in which  
 
Figure 5.1: Spin casting mineral-containing films 
Schematic of spin casting technique as used for generation of mineral-containing films. Parameters were 
developed based on empirical equations defined in (153). Representative micrograph from AFM shown 
on the right. Scale bar represents 2 µm. 
NaCl was used as a porogen. Scaffolds were used to determine if trends observed for 2-D 
mineral-containing films remained true in a 3-D context.  
S
ω = 2000 rpm
t = 60 s
PLG solution droplet with 
dispersed HA particles
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5.3.3 Cell Culture 
All experiments were performed using MDA-MB231 cells (ATCC). Cells were 
maintained under standard culture conditions (37°C, 5% CO2) in complete DMEM (10% FBS 
[Tissue Culture Biologics], 1% PS [Gibco]). Films were sterilized in 70% ethanol for 30 minutes 
and then washed with sterile PBS prior to seeding. Seeded films were also cultured in standard 
conditions within a 6-well tissue culture plate for up to 5 days. 3-D cultures were performed in 
the same way as previously described (108). Cell growth was quantified in two ways. First, cells 
would be trypsined and detached from their substrate and counted using a Coulter Counter 
(Beckman Coulter). Alternatively, cells were lysed in Caron’s Buffer, DNA was labeled with a 
fluorophore (PicoGreen, Invitrogen), and total DNA content was measured using a 
spectrophotometric plate assay.  
5.3.4 IL-8 quantification and inhibitory studies  
24 hours prior to assay time points, culture media was changed to DMEM/1% FBS for 
serum starvation. Upon collection, media was centrifuged to remove cell debris prior to assaying. 
To quantify IL-8, ELISA (R&D) was run on collected media according to manufacturer’s 
instructions. To inhibit integrin αvβ3, a monoclonal antibody against this receptor was used 
(LM609, Millipore). Similarly, an antibody to block the β1-containing integrins was also used 
(MAB17781, R&D systems). Cells were pre-incubated with these antibodies for 30 minutes prior 
to seeding. For inhibition of FAK phosphorylation, the small molecule PF573228 (Tocris) (1 
µM) was included in media, while the small molecule B581 (Sigma) (100 nM) was used to block 
Ras function. Both PF573228 and B581 were tested at various concentrations to determine dose 
response and potential cytotoxicity. While B581 was soluble in aqueous media, because 
PF573228 was only soluble in DMSO, DMSO-only was also tested. All three inhibitors were 
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administered on the day of seeding and were also given during media refreshment 24 hours prior 
to sample collection. After media was collected, it was also characterized for total IL-8 through 
ELISA as described above. 
5.3.5 Statistical Analysis 
All samples were run in triplicate. A confidence interval of 95% was used to determine 
statistical significance (p<0.05) via Student’s t-test or ANOVA in conjunction with Tukey post-
hoc-analysis. Significance was denoted by (*) for results relative to control conditions, while (#) 
was used to indicate specific pairwise comparisons. All data are represented as average ± 
standard deviation.   
5.4 Results 
5.4.1 Effect of integrin inhibition on IL-8 secretion 
In conventional 2-D cultures on plastic, we found that pre-treatment with integrin 
monoclonal antibodies reduced overall cell numbers after 3 days of culture (Fig. 5.2A). This 
effect was observed with inhibition of both αvβ3 and β1. β1 inhibition had a stronger effect on the 
change in cell number, inducing a 36% decrease in cell number. Combined treatment with both 
integrin inhibitors showed a slight synergistic effect, causing a 50% decrease in cell number. 
Conversely, when IL-8 data was analyzed, it was found that αvβ3 inhibition had the stronger 
effect, leading to a 57% decrease in overall secretion (Fig. 5.2B). β1 blocking did not 
significantly affect IL-8 secretion, and use of both antibodies did not produce an effect beyond 
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that observed for αvβ3 alone.
 
Figure 5.2: Effect of integrin inhibition on MDA-MB231 cell behavior 
(A) Number of cells after 3 days of culture with integrin inhibitors as assessed through hemacytometer. 
Results indicate that treatment with inhibitor of β1 causes greatest decrease in cell growth. (B) IL-8 
quantification via ELISA for same experiment shows that only inhibition of αvβ3 attenuates secretion of 
IL-8. (*p<0.05)  
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5.4.2 Effect of downstream signaling targets of integrins on IL-8 secretion 
To determine if known downstream effectors of integrins potentially play a role in 
integrin-mediated IL-8 secretion, inhibitors against FAK (PF573228) and Ras (B581) were 
utilized. Initial studies on dose dependency indicated that neither molecule had a deleterious 
effect on cell health, though PF573228 did cause a slight decrease in cell growth over a 3 day 
period (data not shown). When averaged on a per cell basis, we found that IL-8 secretion is 
significantly reduced with administration of both inhibitors. B581 produced a sharper decrease of 
40% in overall IL-8 levels (Fig. 5.3). 
 
Figure 5.3: Inhibition of FAK and Ras and effects on IL-8 secretion 
Inhibition of FAK phosphorylation (by PF573228) and Ras activation (B581) lead to decreased IL-8 IL-8 
secretion as measured by ELISA. (*p<0.05)  
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5.4.3 Characterization of films 
Since to our knowledge spin-casting of mineral containing polymer films had yet to be 
achieved, we began by attempting varying formulations to yield the ideal surface coating. 
Concentrations of both polymer and mineral were varied to obtain the most uniformly coated 
surface with minimized roughness. Using AFM, spin cast surfaces were microscopically 
inspected and roughness was quantified. Regardless of formulation, all mineral-containing films 
were relatively rough, especially when compared to smooth non-mineral-containing films. 
However, increasing HA content to 8% resulted in a notable decrease in roughness (Fig. 5.4A). 
This is due to less mound formation during spin-casting, as observed in AFM images (Fig. 5.4B). 
Tapping mode was used to calculate overall roughness on a single film initially (thus the lack of 
statistics in Fig. 5.4A). After initial roughness measurement, 8% HA films were selected for 
further evaluation. Film stability and adhesion to the underlying glass slide were evaluated by 
washing in PBS. Weaker film formulations would delaminate and break apart during the washing 
procedure. Increasing the PLG concentration in the original solution to 2% from 1% alleviated 
issues with loss of film integrity. In the end, 8% HA and 2% PLG (weight percentage) were 
found to provide the ideal balance of properties (termed MIN herein).  
5.4.4 Effect of mineral on cell behavior 
After obtaining preliminary evidence that integrin-based signaling could underlie cancer 
cell regulation of IL-8, we next investigated how mineral may further modulate these 
interactions. First, the basic effect of HA in 2-D culture was explored. Over 3 days, cells grew by 
nearly 67% on HA-containing films (MIN). Growth was much slower over the same time period 
on non-HA-containing films (125) at just under 30% (Fig. 5.5A). IL-8 secretion was also 
enhanced on MIN films relative to the NM controls (Fig. 5.5B).   
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5.4.5 Relationship between integrin engagement and HA in promoting IL-8 secretion 
Since we had observed that blockade of the OPN-binding αvβ3 integrin attenuates (Fig. 
5.2) and HA promotes IL-8 secretion (Fig. 5.5), the role of OPN in our system was next tested. 
First, the OPN adsorption capacity of HA was quantified. Examination of the amount of unbound 
protein after incubation with films indicated that MIN films were superior in terms of OPN 
adsorption. In fact, after 1 hour, over 99% of OPN was observed to be stably bound to MIN films 
(Fig. 5.6A). To test if integrin engagement with proteins such as OPN was enough to induce IL-8 
secretion, cells were cultured for 24 hours on MIN films pre-adsorbed with OPN in serum-free 
medium. While culture with OPN did not lead to more IL-8 production than normal culture with 
serum, pre-incubation of cells with the LM609 blocker caused a nearly 4-fold decrease in 
secretion, similar the level of inhibition observed on tissue culture plastic (Fig. 5.6B). Use of 
LM609 in 3-D cultures in non-mineral-containing scaffolds (PLG) and mineral-containing 
scaffolds (PLG/HA) also resulted in a significant reduction in IL-8 secretion (Fig. 5.7). 
 
Figure 5.4: AFM characterization of films 
(A) Initial testing with AFM revealed that increasing HA content in spin casting solution to 8% resulted 
in the smoothest films among mineral-containing group. (B) Representative AFM micrographs of films. 
With 2% HA, formation of large mounds was common. Scales bars represent 2 µm.  (C) Further testing 
0
10
20
30
40
50
60
70
80
R
o
u
g
h
n
e
s
s
 (
n
m
)
2% HA 8% HA
A B C
0
5
10
15
20
25
30
35
40
R
o
u
g
h
n
e
s
s
 (
n
m
) *
107 
with 8%HA and 2% PLG films revealed consistent roughness measurement, indicating acceptable batch-
to-batch variation. (*p<0.05)  
5.5 Discussion 
Because mammary tumors are in the presence of HA both near microcalcifications in the 
breast and eventually in bone after metastasis, understanding the dynamics of their interactions 
might help to determine what drives and causes malignant progression. While HA-containing 
systems have been produced in the past, the role of ECM proteins in modulating cell-HA 
interactions has remained relatively unstudied. Thus, even though it is known that HA is a 
biomaterial that can actively dictate cell behavior (24), the mechanisms by HA directly interact 
with cells are still not totally clear. In this study, mineral-containing films have been employed in 
conjunction with simple inhibitory strategies to help develop a basic signaling model through 
which HA can instruct cellular behavior. Our data suggest that HA may affect cancer cells by 
modulating interactions with ECM proteins, inducing cells to secrete increased levels of pro-
tumorigenic and pro-metastatic cytokines such as IL-8.  
 
Figure 5.5: Cell behavior on films (A) Cell growth on films after 3 days in culture as measured by 
hemacytometer. Results show that MDA-MB231 cells grow more than twice as fast over this time  frame 
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on mineral-containing films (MIN). (B) IL-8 ELISA further indicates that cells also secrete more IL-8 on 
mineral-containing films compared to controls (NM). IL-8 data was normalized on a per cell basis. 
(*p<0.05)  
Cell-ECM interactions are an integral component of the tumor microenvironment. 
Integrins are utilized by cells to anchor to and receive signal inputs from ECM proteins. The 
activity and engagement properties of integrins are known to be dysregulated in a variety of 
cancers (195). In metastatic breast cancer, expression of integrin αvβ3 can be upregulated (196), 
and our findings here suggest that this upregulation may be related to enhanced IL-8 levels. 
Increased levels of IL-8 are clinically observed in a variety of cancers, and this is especially true 
in the case of cancer that exhibit tendency to metastasize to bone (114, 135). Taken together, 
these findings allow us to infer that IL-8 secretion may be microenvironmentally regulated by 
cell-ECM interactions and specifically integrin engagement.  
Interestingly, while blocking αvβ3 with LM609 attenuated IL-8 secretion, β1 inhibition 
did not generate similar results (Fig. 5.3). Physiologically, both of these sets of integrins bind to 
ECM proteins at RGD-sequences. It may be that despite engaging similar ECM proteins, the two 
types of integrins control fundamentally different signaling pathways. β1 inhibition did hinder 
cell growth more effectively (Fig. 5.3), demonstrating that β1 integrins were actively affecting 
overall cell phenotype. Taking this observation into account, our findings suggest that multiple 
integrins control various aspects of behavior that are relevant to tumor progression. In terms of 
inducing IL-8 signaling, we explored several downstream effectors of integrins that are 
associated with the clustering of proteins that takes places during focal adhesion formation. We 
used an inhibitor of FAK phosphorylation (P573228) and were able to show decrease in IL-8 
secretion similar to that observed when using LM609. Furthermore, blocking activation of Ras, a 
protein that is known to be connected to pFAK and can induce transcriptional signals (197) also 
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produced a drop in IL-8 levels. The fact that blocking each of these signaling molecules 
produced the same effect in the context of IL-8 strongly suggests that they are involved in 
inducing its production. Indeed, Src, which has been shown in other studies to be heavily 
involved in IL-8 transcription (179, 198, 199), is part of a well-known signaling cascade that is 
initiated by FAK and involves Ras (200). While inhibition of Ras had a definite effect on IL-8, it 
did not alter cell growth, indicating that the pathway by which β1 integrins might promote 
mitogenic activity is fundamentally different than the one proposed here for IL-8 production.  
Microcalcifications are a common feature associated with mammary tumors. They 
represent one of the most important diagnostic markers used in contemporary medicine. While 
their presence has been used clinically, this utility has been limited to helping surgeons identify 
tumor margins (201). Past work from our studies and others indicates that HA may actually 
actively affect metastatic progression (23, 108). Clinical data further suggests that 
microcalcifications composed of highly crystalline HA have greater than 90% sensitivity in 
predicting metastasis to bone (27). Understanding how HA can instruct cell behavior might be 
important to determining how microcalcifications influence metastagenicity. Here, our findings 
implicate HA in promoting both tumor cell growth and IL-8 secretion (Fig. 5.5). These results 
corroborate studies with HA in other culture models (24, 63), but our studies further demonstrate 
that these effects are directly mediated by adsorption of RGD-containing proteins such as OPN 
(Fig. 5.6B). Comparison with a 3-D model indicates that integrin blockade similarly affects cells 
in scaffolds, ensuring that our findings are not an artifact of 2-D culture. 2-D culture may in fact 
be physiologically relevant for this case, because cellular interactions with mineral at the 
nanoscale are largely polarized and planar, as for example with osteoclasts (202). OPN has been 
found to be overexpressed in many mammary tumors, and high levels in the ductal structures are 
110 
correlated specifically with bone metastasis (31, 56, 203). As our data show, HA as presented in 
microcalcifications adsorbs OPN extremely effectively (Fig. 5.6A). Potentially, 
microcalcifications act as sinks for OPN, which is not typically found in non-lactating breast 
tissue, thereby providing a specific ECM motif that can stimulate production of IL-8 and help to 
initiate bone metastasis.
 
Figure 5.6: OPN adsorption on films and effect of αvβ3 inhition 
(A) Bicinchonic assay (BCA) shows that OPN adsorption is enhanced on mineral-containing films. (B) 
Measurement of IL-8 by ELISA shows that OPN alone allows cells to secrete IL-8, and that blocking 
integrin αvβ3 causes decrease in this secretion. (*p<0.05)  
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Figure 5.7: IL-8 secretion under integrin inhibition in 3-D  
ELISA on 3-D conditioned media shows that blocking integrin αvβ3 reduces IL-8 production in mineral-
containing scaffolds also.  
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Though this study helped to elucidate potential mechanisms by which HA in 
microcalcifications can influence malignant cell behavior, several limitations exist. The effect of 
HA properties on protein adsorption have been neglected, as commercial mineral has been used. 
Other studies have illustrated that adsorption capacity and even the types of proteins adsorbed 
may differ if mineral properties change (59). It is possible that changes in mineral properties 
could also affect protein folding. Given the distinct difference that we observed in cell behavior 
in response to blocking integrins αvβ3 and β1, it is worth noting that preference for engagement 
could be modulated by changes in folding. β1 integrins like α5β1 require the proximity of a 
“synergy site” for effective engagement (204), while no such requirement exists for αvβ3. In both 
fibronectin, the predominant peptide found in serum, and osteopontin, the synergy site’s 
proximity to the RGD-sequence is controlled by protein-folding (205). When proteins become 
unfolded, the synergy site can be too far from the RGD-sequence to allow effective integrin 
engagement. It is possible that this type of phenomenon affected our findings. Further, while 
MDA-MB231 cells represent an excellent model for aggressive breast cancers, integrin 
expression is extremely heterogeneous across cancer populations, making it difficult to 
definitively characterize a single integrin as being solely responsible for a response as important 
as IL-8 secretion. Still, since past studies have shown that HA promotes IL-8 response in a host 
of cell lines (63), it is likely that the findings here reflect an actively important mechanism for 
production of pro-metastatic cytokines. 
The generation of systems that incorporate HA for presentation to cells is an emerging 
and growing research interest. It is increasingly apparent that cell-mineral interactions play a role 
in the pathogenesis of mammary and other tumors. By developing a film system that easily 
enables uniform protein adsorption, we have been able to gain basic insights into how cell 
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behavior can be dictated by mineral. Though 3-D systems offer an increased level of complexity 
for recapitulating physiological microenvironments, the film system enabled simpler evaluation 
of basic protein adsorption and its relationship to cell behavior. Because cell-HA interactions 
produced similar response in both 2-D and 3-D, and because planar systems are more amenable 
to a diversity of imaging techniques, there is strong potential for future implementation of the 
films for further study of cell-mineral interactions. With a stronger understanding of how 
specifically mineral drives the progression of cancer, the community is better equipped to 
identify new and potentially more efficacious targets for therapies.  
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CHAPTER 6: CONCLUSIONS 
In total, the studies outlined herein show that HA can be deeply involved in the metastatic 
cascade that ensues when breast cancer advances to and colonizes the skeleton. Overall findings 
have provided insights that are valuable not just to cancer biology, but also to the fields of tissue 
engineering and biomaterials science in the context of tumor model development. Mammary 
tumor cell interactions with mineral and the factors facilitating and controlling these interactions 
were studied within engineered material systems to reveal biomolecular mechanisms and 
cytokine signaling networks that underlie bone metastasis. Furthermore, the relationship between 
HA materials properties and cellular activity was illuminated, and the vast potential for using 
carefully-defined synthetic HA in biomedical engineering was explored. Since breast cancer cells 
are exposed to mineral at both the primary and metastatic site in the form of microcalcifications 
and bone, respectively, the development of tools to specifically investigate how cells interface 
and respond to mineral may prove useful in the identification of novel therapeutic possibilities. 
Moreover, because tissue engineering principles were used to conceive the systems utilized in 
these studies and because HA has been identified as a bioactive material that is being 
increasingly employed in implants, the potential tumorigenic effects of mineral that were 
highlighted are especially crucial to understand. The overriding research plan was performed to 
specifically investigate three major concepts that as a whole aimed to confirm the original 
hypothesis that mammary tumor cell-mineral interactions essentially promote the directed 
formation of osteolytic metastases in bone. These three conceptual questions are specifically 
defined in section 1.6. 
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6.1 Mineral promotes osteoclastogenesis by enhancing tumor cell secretion of osteolytic 
factors 
The phenomenological relationship between HA and MDA-MB231 cells was first 
studied. Changes in cell behavior were studies in terms of how they may functionally promote 
the osteolytic phenotype observed in skeletal metastases originating from mammary tumors. This 
was accomplished by using a biomaterials system that was designed based on tissue engineering 
principles. The fabrication of gas-formed/particulate leached HA-containing scaffolds and their 
use as platforms for research of cancer biology was described (Chapter 2). Initial investigations 
focused on confirming that cells were appropriately exposed to mineral within this scaffold 
system, and subsequently, a variety of assays was used to determine how cell behavior varied in 
mineral-containing scaffolds relative to non-mineral-containing controls. Specific increases in 
IL-8, a molecule established as having the capability to drive osteolytic activity, were observed 
for MDA-MB231 cells. Further evidence to corroborate these findings was presented in Chapter 
3, where it was demonstrated that DCIS cell lines exhibited similar behavior in mineral-
containing scaffolds. Taken together, these results suggest that cell-HA interactions certainly 
may promote osteoclast differentiation via soluble IL-8. 
Initially, the surface presence of HA in scaffolds was assessed through a variety of 
physicochemical characterization techniques including EDS, microCT, and microscopic 
inspection (Fig. 2.1). More careful inspection with electron microscopy showed definitively that 
HA was available to cells within scaffold pores (Fig. 4.5-6). Observation of cell attachment to 
scaffolds revealed that HA enabled a pronounced adhesion advantage for breast cancer cells 
upon static seeding. Not only did quantitative analysis demonstrate more cells in the scaffold in 
total, histological analysis showed that cells were able to adhere in the innermost pores of only 
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mineral-containing scaffolds (Fig. 2.2). Cell growth and IL-8 secretion were also higher in 
mineral-containing scaffolds, and through use of conditioned media, we saw that this tumor-
derived IL-8 did indeed cause a dramatic increase in differentiation of RAW 264.7 osteoclast 
precursor cells. Analysis on mineral-containing surfaces showed that resorptive activity was also 
increased in the presence of conditioned medium from mineral-containing cultures and that this 
effect was mediated by IL-8 at least in part (Fig. 2.4-5).  
Though these studies taken together certainly provided evidence that HA altered breast 
cancer cell behavior in a functional manner, a molecular understanding of these phenomena was 
not yet developed. Other potential molecular players were still not identified, mediators of cell-
HA interactions had not been studied, and the avidity for bone displayed by breast cancers was 
unexplored. Furthermore, the value of attempting to recapitulate bone with the scaffold was still 
undetermined, as skeletal mineral differs significantly in terms of distribution in tissue, 
composition, and material properties from the commercial HA we had used. Still, this initial 
work did demonstrate that the scaffold system was effective for probing cell-mineral 
interactions, and it was indicated that the model may be suited to study microcalcifications, a 
common feature in mammary tissue for metastatic breast cancer. With these limitations 
acknowledged, it was clear that further analysis with the scaffold system could help in 
elucidating how cell-HA interactions were pathologically relevant. 
6.2 Exposure to microcalcifications/mineral primes mammary tumor cells for 
colonization of bone by stimulating MSC-driven recruitment  
In studying pathological relevance, mineral-containing scaffold models were again 
utilized, this time to model tumor cell interactions with microcalcifications in the breast tissue 
(Chapter 3). A wider analysis on HA-regulated changes in gene expression was performed. 
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Functional consequences of alterations in breast cancer cell behavior as regulated by HA were 
also explored further, including effects on driving bone-directed migration through stimulation of 
MSCs. Studies on other cell types in scaffolds were carried out. Significantly, it was found that 
MCF10A-DCIS cells, a model representing breast cancer cells that are not fully committed to 
metastasis, were impacted by the presence of mineral similarly to MDA-MB231 cells. Beyond 
this, it was observed that metastatic site-specific subpopulations of MDA-MB231 cells all 
exhibited preference to colonize bone following exposure to HA. Finally, clinical insights were 
obtained by studying the correlation between mineral, molecular phenotype, and disease 
outcome in patient samples. The findings from all of these studies helped to demonstrate the 
validity of the second important concept of overriding hypothesis that the presence of HA could 
act in a pro-metastatic manner by initiating chemoattraction to stromal cells in bone. 
From a disease perspective, DCIS cells are very relevant in study cell-mineral 
interactions, because microcalcifications are often found to be associated with DCIS cases. 
Further, comedo-type DCIS, which are most prone to progressing to invasive carcinoma, are 
frequently diagnosed through mammograms indicating the presence of microcalcifications. An 
elevation in secreted IL-8 by DCIS cells in the mineral-containing scaffolds helped to 
corroborate earlier findings with MDA-MB231 cells (Chapter 2), and also represented a major 
step in proving the physiological relevance of the model. More extensive molecular 
characterization of the scaffolds revealed that not only were IL-8 levels affected, but genes that 
had been identified as part of a genetic signature associated with bone metastasis were also 
upregulated in the presence of HA (Figure 3.3). This finding held true not just for parental MDA-
MB231 cells, but also for subpopulations that had previously been identified as lung-specific 
(4175), indicating that, to some degree at least, expression of the bone metastasis gene signature 
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is microenvironmentally controlled. Additional confirmation of this was attained by injecting 
these cells into mice following culture in mineral-containing scaffolds, as they showed a 
tendency to colonize bone. In the bone, histological analysis provided evidence of osteolysis 
mediated by the colonizing 4175 cells. Along with the results presented in Chapter 2, there was 
now a strong suggestion that mineral promotes an overall metastatic and osteolytic phenotype.  
Subsequent experiments involved understand the molecular mechanisms that might 
underlie HA-regulated metastasis to bone. These efforts demonstrated that tumor-derived IL-8 
may play an additional role in eliciting SDF-1 secretion by MSCs, cells naturally found in the 
bone microenvironment. Through inhibition studies, we discovered that MSCs responded to IL-8 
via the CXCR1 receptor and then dramatically increased their production of SDF-1 (Fig. 3.4A-
B). In turn, it was found that these enhanced SDF-1 concentrations were capable of inducing 
breast cancer cell migration via chemoattraction. Transcriptional analysis had shown that 
upregulation of CXCR4 by breast cancer cells occurred in the presence of HA, and Western blot 
and immunofluorescence confirmed that surface presentation of the receptor also increased. 
Since CXCR4 is the cognate receptor for SDF-1, we postulated that migration may be taking 
place along the SDF-1/CXCR4 axis and that this cascade was initiated by IL-8 secretions. By 
separately inhibiting each of these, it was determined that this molecular model was valid (Fig. 
3.4D). Mammary tumor cell interactions with HA cause increased secretion of IL-8, which 
drives SDF-1 production by MSCs. In this way, tumor cells are able to induce their own 
migration in response to HA. Additionally, HA stimulates increased concentrations of the SDF-1 
receptor for tumor cells, thereby sensitizing their migratory reaction. While the scaffold system 
enabled the development of this fairly robust model, to truly evaluate its validity, these molecular 
players needed to be studied in a more pathologically relevant context. To this end, a panel of 
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clinical breast samples was assessed. Though only preliminary data was available, initial 
observations were promising. In localized analysis of individual ductal structures, there was a 
correlation between invasiveness and IL-8 level. Gross analysis was limited by lack of benign 
samples; however, there was at least marginal correlation between the appearance of 
microcalcifications and IL-8 levels. CXCR4 immunofluorescence also showed a correlation 
between the appearance of IL-8 and CXCR4 in ducts.  
The overall findings presented in Chapter 3 presented an additional level of relevance to 
actual disease states by integrating the results from the scaffolds system with experiments in 
animal models and with clinical samples. The functional significance of results with IL-8 in 
Chapter 2 was explored, leading to the generation of a molecular model for HA-regulated 
metastasis to bone. To expand our understanding of how HA might initiate this complex 
cytokine signaling cascade underlying bone metastasis, the dynamics involved in mediating cell-
mineral interactions needed to be studied in more detail.    
6.3 Crystal properties modulate cell-ECM interaction to alter tumor cell behavior and 
regulate the malignant phenotype 
Cell-mineral interactions in the tumor microenvironment need to be studied in two ways 
for a comprehensive understanding of how they affect disease. First, the downstream effects on 
cells need to be studied to understand how cell behavior is altered in terms of adhesion, 
proliferation, gene expression, secretory behavior, and other relevant properties that drive 
observed phenotypes. Much of this was studied in Chapters 2 and 3. Second, the fundamental 
mechanisms by which mineral can affect cells must be understood. Thus, the effects of changes 
in HA material properties and the modulation of cell-mineral interactions by ECM proteins was 
finally assessed (Chapters 4 and 5). In the concluding studies, techniques to synthesize well-
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defined HA particles and incorporate these into 3-D culture platforms were used to show that 
changes in crystal properties strongly affected interactions with cells, altering growth and IL-8 
secretion patterns (Chapter 4). A 2-D film system that allowed simpler analysis of how ECM 
proteins such as OPN controlled cell-HA interactions was also used, showing that integrin 
engagement likely plays a critical role in many of our IL-8 findings  (Chapter 5). 
Hydrothermal aging was used to synthesize HA with tunable crystallinity and particle 
size (Fig. 4.1). This novel process relied on separation of the precipitation and aging steps in 
creating HA. The stark contrast in monodispersity and crystal properties between our synthetic 
HA and commercially available HA can be observed in Fig. 4.2-3. A batch of HA particles with 
steadily increasing size and crystallinity was created and incorporated into the scaffold model. 
Significant differences in serum protein adsorption were found amongst the populations of 
crystals in scaffolds. Specifically, as HA crystallinity particle size decreased, protein adsorption 
increased (Fig. 4.6). Similar trends were observed for cell growth and adhesion on the scaffolds 
containing synthetic HA as well (Fig. 4.7). Conversely, IL-8 secretion increased with increasing 
size and crystallinity (Fig. 4.8). Highly crystalline HA is generally not found in bone, but 
microcalcifications sometimes contain this type of mineral. In fact, microcalcifications that are 
most crystalline and possess the least amount of carbonate substitution are associated with the 
greatest tendency to invasion in mammary tumors (27). In this context, our findings that highly 
crystalline stimulates the most IL-8 may be physiologically relevant. Furthermore, the 
observation that low crystallinity stimulates enhanced adhesion may be related to one advantage 
for tumor cells to metastasize to bone: because bone mineral is generally of low crystallinity, it 
would have high adhesive capacity and would be suitable for colonization by circulating tumor 
cells. 
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Given these first insights into how HA properties and protein adsorption affects tumor 
cell behavior, it was next important to understand how ECM proteins were involved in cell-HA 
interactions. The role of integrin engagement in IL-8 secretion was studied, revealing that 
integrin αvβ3 may be involved in stimulating IL-8 upon focal adhesion formation. Inhibition of 
downstream signaling targets (FAK and Ras) of this integrin further supported this idea (Fig. 5.2-
3). The relationship of integrin binding to IL-8 secretion in conjunction with findings from the 
previous chapter that protein adsorption was a major determinant of cell behavior led us to use 2-
D mineral-containing films for further studies. We observed that exposure to IL-8 enhanced 
cellular growth and secretion of IL-8 in 2-D, just as it did in 3-D (Chapter 2). It was also found 
that OPN was preferentially adsorbed on mineral-containing films and could stimulate IL-8 
production via engagement of αvβ3 (Fig. 5.6). High levels of OPN are a defining feature of 
metastatic breast cancers, and our results had indicated that OPN upregulation occurs in the 
presence of HA (Chapter 3). In sum, it becomes clear that mineral properties and interactions 
with adhesive proteins like OPN are integral in driving bone metastasis.  
This work demonstrated the need for understanding the dynamics of the relationship 
between HA and cells. Materials properties were found to play a major role in affecting how 
mammary tumor cells interact with mineral. Hydrothermal aging has emerged as a valuable tool 
to create well-defined HA that can be used to study biological phenomena. Since HA changes as 
a function of human development and disease, hydrothermally aged particles may be useful in a 
wide array of culture systems and biomedical applications. The underlying importance of protein 
adsorption and integrin engagement in dictating cell-material interactions was demonstrated with 
the use of the film system. Though integrins are already known to be extremely multifunctional, 
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these experiments have provided yet another context in which integrin engagement influences 
disease progression.  
6.4 Future Directions 
The total results of this work have several major implications. Firstly, the importance of 
biomaterials and scaffold systems for use as in vitro platforms to study cancer biology has been 
highlighted. By using tissue-engineering inspired techniques, we were able to study a range of 
phenomena, including cell-mineral interactions, that are not easily examined in conventional 
culture. HA has been identified as a major player in breast cancer metastasis, and our techniques 
to synthesize this mineral in a controlled manner and incorporate them into a scaffold culture 
system were highly successful. Secondly, this dissertation has provided fundamental evidence to 
support a thorough molecular model by which HA in microcalcifications can drive breast cancer 
metastasis to bone. OPN, which is observed in clinical breast tumors, was shown to be 
upregulated in response to HA and also to adsorb to HA and induce IL-8 secretion. IL-8 
secretion was observed to stimulate production of SDF-1, which acts as a chemoattractant for 
breast cancer cells, and also to be involved in osteolysis at the metastatic site. HA was 
additionally found to stimulate expression of the SDF-1 receptor, CXCR4, making cancer cells 
even more sensitive to chemotactic effects and migration to bone. These findings are promising, 
but future work is needed to totally understand the role of HA in cancer pathogenesis and to 
translate insights gained in this thesis to practical use.  
6.4.1 Genesis and characterization of microcalcifications  
This thesis project has focused on the interactions that occur between mammary tumor 
cells and the pathological ramifications of their relationship. A comprehensive understanding of 
the role of mineral in breast cancer further requires insight into how microcalcifications form. In 
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the medical community, several potential explanation form microcalcifications exist, including 
adipose cell necrosis, tissue fibrosis, and sclerosing adenosis (206, 207). These phenomena are 
all passive effects associated with the hyperproliferative and potentially hypoxic 
microenvironment generated by the development of mammary tumors (208). However, given the 
active role that our results suggest for mineral in promoting metastasis, it is logical that tumor 
cells themselves may contribute to the genesis of microcalcifications. Future work should be 
directed at determining if active mineralization is a feature preceding metastasis. Preliminary 
work in our lab indicates that tumor-derived soluble factors can promote stromal cell-mediated 
tissue mineralization. MDA-MB231 subpopulations with previously established bone-specific 
metastatic phenotype, in particular, promoted enhanced mineralization. Further experiments 
should be aimed at identifying specific soluble factors that can promote stromal cell 
mineralization. Additionally, it will be important to determine how stromal cells can mineralize 
tissue. Knowledge gained in these endeavors will not only assist in learning about 
microcalcifications in breast cancer, but also in other diseases like atherosclerosis and valvular 
calcifications where ectopic mineralization is a key feature. If the mechanisms of the signaling 
pathways that drive ectopic calcification are elucidated, a range of new and innovative anti-
mineralization therapies may also become viable. 
Recent evidence has shown that the composition of microcalcifications is a valuable 
predictive factor for determining the likelihood of metastasis to bone (26, 27). Based on our 
findings showing that changes in mineral material properties actually alter cellular interactions, 
the effect of composition should be studied more extensively. Specifically, increasing levels of 
carbonate substitution in HA have been correlated with decreased risk for metastasis. With our 
ability to synthesize HA with tunable properties, altering carbonate concentrations is possible, 
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and a new series of particles should be synthesized and incorporated into the scaffold system. 
Effects on IL-8 secretion and expression of the bon metastasis genetic signature should be tested 
in the presence of these carbonated apatites. Calcium oxalate dihydrate is another mineral 
associated with non-malignant lesions of the breast (209, 210), and scaffolds incorporating this 
oxalate particles could be used as valuable controls for future studies. By completely 
understanding the role of mineral properties in modulating the molecular phenotype of tumor 
progression, it may become possible develop more effective and personalized treatment regimes 
earlier in the diagnostic process.  
While creating particles with varying composition and phase for incorporation into the 
scaffold models is very important in revealing the molecular players that are associated with 
states of microcalcification, the reverse approach is also possible given the findings of this 
dissertation. With access to clinical samples, it is possible to in the future perform a robust 
battery of materials testing on human tissue to determine the specific characteristics of 
microcalcifications. Where past studies have shown preliminary data on the relation between 
mineral phase and composition and disease outcome, the work presented in this dissertation has 
equipped us with tools to develop a more comprehensive understanding of how crystals can 
affect disease. Using a combination of XRD, FTIR, and other characterization tools, it may be 
possible to translate our findings with hydrothermally aged particles to these clinical samples, 
testing the effects of particle size and overall crystallinity. Additionally, because we have used 
our mineral-containing scaffolds as a platform to develop an understanding of the molecular 
basis of bone metastasis, immunostaining and biomolecular techniques can be used to analyze 
human tissue for factors shown to be significant in vitro. By combining the materials approach 
with the biomiolecular approach, a truly comprehensive model of breast cancer metastasis to 
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bone with unprecedented detail can be developed, showing the connection between nanoscale 
material properties, molecular phenotype of cells, and patient outcome. Such a model would be 
of tremendous value for clinical treatment and diagnosis. 
6.4.2 Mediators of cell-HA interactions 
Experiments in this body of work provided strong evidence that RGD-containing ECM 
proteins such as OPN and fibronectin may dictate interactions between cells and HA. However, 
future work must clarify how these proteins are involved in changes of cell behavior with 
varying mineral properties. Current examinations were limited to experiments with commercially 
available HA, but use of our synthetic HA instead will provide a more complete understanding of 
these dynamics. A starting point for these future studies might involve investigating cell 
spreading and morphological changes as a function of changes in mineral properties. The 
development of a planar system, such as the one introduced in chapter 4, but incorporating 
synthetic well-defined HA, would facilitate such analyses. Similar approaches in terms of OPN 
adsorption and integrin blocking should be undertaken on these planar surfaces, and additional 
assessment of focal adhesion formation and colocalization of specific integrins with OPN will 
provide useful information on the interplay between RGD-containing proteins, HA, and breast 
cancer cells. Protein binding to the surface should also be studied in the absence of cells. While 
the studies presented in this dissertation showed differences in the quantity of protein adsorption, 
it will also be possible to explore how proteins fold differently as a function of mineral 
characteristics. For this, the single-molecule FRET technique can be employed, allowing 
quantification of protein folding for molecules like fibronectin (21). These proposed studies 
might reveal why different patterns and types of HA stimulate such stark differences in disease 
progression, potentially further increasing the diagnostic value of mammograms. 
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6.4.3 Role of native bone cells in pre-metastatic niche formation 
The initial studies presented in this thesis demonstrated that tumor-derived soluble factors 
can have tangible effects on native bone cell function, including driving osteoclast activity and 
stimulating secretory function from hMSCs. It is also possible that hematopoietic stem cells 
(HSCs) are involved in priming the bone microenvironment for metastasis. Previous studies have 
shown that HSCs can also secrete SDF-1 and may act to induce cancer cell migration (55). 
Additionally, HSCs are the capable of generating osteoclasts through differentiation, and it has 
been observed that HSC mobilization is involved in the coordination of bone homeostasis (211). 
Future studies should focus on looking at how HA-regulated tumor-derived soluble factors affect 
HSC proliferation, differentiation, and secretion of pro-migratory factors in a manner similar to 
studies performed in this dissertation with MSCs. In terms of tumor-derived soluble factors 
promoting enhanced osteoclast activity, the possibility that these communications take place 
even before cancer cells leave the primary tumor should be investigated. For instance, future 
work might focus on understanding how cancer cell-mediated changes to the bone 
microenvironment may be part of the establishment of a pre-metastatic niche. If cancer cells are 
capable of altering osteoclast or osteoblast function in an endocrine manner, perhaps changes in 
bone ensue prior to colonization. Endocrine signaling by IL-8 may promote skeletal excavation 
by osteoclasts ahead of metastasis, enriching the bone microenvironment with growth factors, 
increasing trabecular surface area available for colonization, and generally creating conditions 
favorable for tumor growth. Xenograft studies in mice, where tumors will not colonize bone 
under normal conditions, may allow the examination of the effect of increased levels of IL-8 on 
bone degradation. MicroCT and histological analysis can be used to show changes in bone 
parameters such as trabecular geometry and bone volume fraction that are mediated by a distant 
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tumor. If osteolysis is a precursor to metastasis, it may additionally play a role in 
microcalcification formation: past studies have indicated that hypercalcaemia, which can be 
initiated by overactive osteoclasts, may play a role in facilitating ectopic calcifications during 
breast cancer (212, 213). Thus, the proposed mouse study could also entail measuring plasma 
levels of Ca
2+
, and looking at the xenografts for the formation of microcalcifications through 
histopathological analysis.  
6.4.4 Therapeutic targets 
The contribution to the development of better therapeutic options is always on of the 
main goals for a dissertation in cancer-related fields. While the majority of the work here was 
performed primarily to develop fundamental insights into cancer biology and the utility of 3-D 
biomaterial culture systems, it is hoped that some of the findings can be translated into the 
generation of more efficacious treatments at some point in the future. In this work, the basic 
importance of IL-8 in promoting metastasis via the SDF-1/CXCR4 axis was highlighted. To truly 
cross-validate these findings with clinical models, a future extension of the clinical study 
described in Chapter 3 should be undertaken. Local correlations between microcalcifications, 
CXCR4 levels, and IL-8 should be explored. Concurrently, analyzing patient plasma samples to 
check SDF-1 levels would be insightful. Still, based on the current work, targeting IL-8, SDF-1 , 
or CXCR4 would be a promising strategy to curb breast cancer metastasis to bone. These 
approaches have been variously explored. Inhibitors of IL-8 signaling are currently in clinical 
trials (115) as is blockade of the SDF-1/CXCR4 axis by small molecule inhibition of the receptor 
(214). Given the heterogeneity of cancer, and the fact that IL-8 receptors can be bound by other 
ligands (215, 216), future work might also explore alternative mechanisms that can activate 
metastatic signaling.     
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Since therapies focused on the cytokine signaling network exist, future work may also 
involve investigating phenomena that may help to generate other types of therapies. One concept 
that needs to be understood further is the use of bisphosphonates. Currently, this class of drugs is 
prescribed universally for osteoporosis, but it has also been used in cases of osteolytic metastasis 
(35, 212). Bisphosphonates function by adsorbing to bone mineral by virtue of their phosphate 
groups and killing osteoclasts that take up the drug by interfering with biosynthesis. In Chapter 
2, we showed that the bisphosphonate ibandronate preferentially targeted breast cancer cells in 
mineral-containing scaffolds for death. Future work should expand on this finding, to determine 
the mechanism by which bisphosphonates can kill cancer cells. Also, in the context of the 
hypothesis that osteoclastic activity is a necessary precursor for metastasis, the use of 
bisphosphonates in preventing metastasis may be an option. Since bisphosphonates prevent 
resorption, perhaps prophylactic administration to patients with non-disseminated DCIS or 
increased breast cancer risk factor will prevent colonization of bone. In the proposed future work 
with mice on investigating formation of a pre-metastatic niche, dosing with bisphosphonates as a 
bone protective drug could also be tested. While some recent clinical trials have indicated the 
prophylactic bisphosphonate treatment may indeed inhibit metastatic disease (217), long term 
use of bisphosphonates is not ideal; side effects include increased risk for pathological fracture 
(218), esophageal inflammation, and perhaps even esophageal cancer (219). Future work with 
our system could investigate the ability to inhibit osteoclast activity temporarily or through a 
specific molecular mechanism that does not completely de-regulate the entire system of skeletal 
turnover. For instance, inhibition of soluble IL-8 could work as a preventative measure against 
osteolysis-mediated pre-metastatic niche formation. Beyond this, by working with the mineral-
containing culture system and osteoclast precursor cells further, molecular insights into how to 
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inhibit enhanced osteoclast activity in the presence of tumor-derived soluble factors without 
destroying this cellular population may be revealed. 
One final therapeutic concept that might be explored could involve directly interfering 
with microcalcification formation. Future work that focuses on determining the origin of 
microcalcifications may uncover molecular factors that are crucial to the genesis of ectopic 
calcification in mammary tissue. Inhibitory strategies against these molecules may be effective in 
preventing mineralization and destroying the metastatic cascade described by our model. Since 
hypercalcaemia is also likely playing a role in formation of microcalcifications, therapies to 
scavenge extra plasma Ca
2+
 may be effective. These might include strategies such as calcium 
dialysis, which are usually employed for patients with renal-failure associate hypercalcaemia 
(220, 221). Overall, the breadth of strategies covered here is not a complete list, but the diversity 
of the proposed option reflects the potential practical utility of the work performed and the 
systems develop over the course of this thesis work.    
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